[go: up one dir, main page]

US6015695A - Immunoglobulins devoid of light chains - Google Patents

Immunoglobulins devoid of light chains Download PDF

Info

Publication number
US6015695A
US6015695A US08/468,739 US46873995A US6015695A US 6015695 A US6015695 A US 6015695A US 46873995 A US46873995 A US 46873995A US 6015695 A US6015695 A US 6015695A
Authority
US
United States
Prior art keywords
seq
sequence
immunoglobulin
dna
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/468,739
Other languages
English (en)
Inventor
Cecile Casterman
Raymond Hamers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel VUB
Original Assignee
Vrije Universiteit Brussel VUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26132410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US6015695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP92402326A external-priority patent/EP0584421A1/en
Application filed by Vrije Universiteit Brussel VUB filed Critical Vrije Universiteit Brussel VUB
Priority to US08/468,739 priority Critical patent/US6015695A/en
Assigned to VRIJE UNIVERSITEIT BRUSSEL reassignment VRIJE UNIVERSITEIT BRUSSEL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASTERMAN, CECILE, HAMERS, RAYMOND
Application granted granted Critical
Publication of US6015695A publication Critical patent/US6015695A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Definitions

  • the invention relates to new isolated immunoglobulins which are devoid of light polypeptide chains. These immunoglobulins do not consist in the degradation products of immunoglobulins composed of both heavy polypeptide and light polypeptide chains but to the contrary, the invention defines a new member of the family of the immunoglobulins, especially a new type of molecules capable of being involved in the immune recognition. Such immunoglobulins can be used for several purposes, especially for diagnosis or therapeutical purposes including protection against pathological agents or regulation of the expression or activity of proteins.
  • immunoglobulins consists of a four-chain model referring to the presence of two identical light polypeptide chains (light chains) and two identical heavy polypeptide chains (heavy chains) linked together by disulfide bonds to form a y- or T-shaped macromolecules. These chains are composed of a constant region and a variable region, the constant region being subdivided in several domains.
  • the two heavy polypeptide chains are usually linked by disulphide bounds in a so-called "hinge region" situated between the first and second domains of the constant region.
  • proteins forming the class of the immunoglobulins most of them are antibodies and accordingly present an antigen binding site or several antigen binding sites.
  • the antigen binding site of an antibody is located in the variable domains of each of the heavy and light chains, and requires the association of the heavy and the light chains variable domains.
  • the inventors have surprisingly established that different molecules can be isolated from animals which naturally produce them, which molecules have functional properties of immunoglobulins these functions being in some cases related to structural elements which are distinct from those involved in the function of four-chain immunoglobulins due for instance to the absence of light chains.
  • the invention relates to two-chain model immunoglobulins which neither correspond to fragments obtained for instance by the degradation in particular the enzymatic degradation of a natural four-chain model immunoglobulin, nor correspond to the expression in host cells, of DNA coding for the constant or the variable region of a natural four-chain model immunoglobulin or a part of these regions, nor correspond to antibodies produced in lymphopaties for example in mice, rats or human.
  • variable domains of heavy polypeptide chains V H
  • V K /F V variable domains of heavy polypeptide chains
  • V H domains are relatively sticky, presumably due to the exposed hydrophobic surface normally capped by the V K or V.sub. ⁇ domains. They consequently envisage that it should be possible to design V H domains having improved properties and further that V H domains with binding activities could serve as the building blocks for making variable fragments (Fv fragments) or complete antibodies.
  • the invention does not start from the idea that the different fragments (light and heavy chains) and the different domains of these fragments of four-chain model immunoglobulin can be modified to define new or improved antigen binding sites or a four-chain model immunoglobulin.
  • immunoglobulins can have a different structure than the known four-chain model and that such different immunoglobulins offer new means for the preparation of diagnosis reagents, therapeutical agents or any other reagent for use in research or industrial purposes.
  • the invention provides new immunoglobulins which are capable of showing functional properties of four-chain model immunoglobulins although their structure appears to be more appropriate in many circumstances for their use, their preparation and in some cases for their modification. Moreover these molecules can be considered as lead structures for the modification of other immunoglobulins.
  • the advantages which are provided by these immunoglobulins comprise the possibility to prepare them with an increased facility.
  • the invention accordingly relates to immunoglobulins characterized in that they comprise two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, these immunoglobulins being further devoid of light polypeptide chains.
  • these immunoglobulins are further characterized by the fact that they are the product of the expression in a prokaryotic or in a eukaryotic host cell, of a DNA or of a cDNA having the sequence of an immunoglobulin devoid of light chains as obtainable from lymphocytes or other cells of Camelids.
  • the immunoglobulins of the invention can be obtained for example from the sequences which are described in FIG. 7.
  • the immunoglobulins of the invention which are devoid of light chains are such that the variable domains of their heavy chains have properties differing from those of the four-chain immunoglobulin V H .
  • the variable domain of a heavy-chain immunoglobulin of the invention has no normal interaction sites with the V L or with the C H 1 domain which do not exist in the heavy chain immunoglobulins. it is hence a novel fragment in many of its properties such as solubility and position of the binding site. For clarity reasons we will call it V HH in this text to distinguish it from the classical V H of four-chain immunoglobulins.
  • a complete antigen binding site it is meant according to the invention, a site which will alone allow the recognition and complete binding of an antigen. This could be verified by any known method regarding the testing of the binding affinity.
  • immunoglobulins which can be prepared by the technique of recombinant DNA, or isolated from animals, will be sometimes called "heavy-chain immunoglobulins" in the following pages. In a preferred embodiment of the invention, these immunoglobulins are in a pure form.
  • the immunoglobulins of the invention are obtainable in prokaryotic cells, especially in E.coli cells by a process comprising the steps of:
  • the immunoglobulins are obtainable by a process comprising the steps of:
  • Successful expression can be verified with antibodies directed against a region of a V HH domain, especially by an ELISA assay.
  • the immunoglobulins are cloned in a parvovirus.
  • these immunoglobulins are obtainable by a process comprising the further cloning of a second DNA or cDNA sequence having another determined antigen binding site, in the pMM984 plasmid.
  • Such an Immunoglobulin can be further characterized in that it is obtainable by a process wherein the vector is Yep 52 and the transformed recombinant cell is a yeast especially S.cerevisiae.
  • a particular Imunoglobulin is characterized in that it has a catalytic activity, especially in that it is directed against an antigen mimicking an activiated state of a given substrate.
  • These catalytic antibodies can be modified at the level of their biding site, by random or directed mutagenesis in order to increase oe modify their catalytic function.
  • the immunoglobulins of the invention are characterized in that their variable regions contain in position 45, an amino-acid which is different from leucine, proline or glutamine residue.
  • the heavy-chain immunoglobulins are not products characteristic of lymphocytes of animals nor from lymphocytes of a human patient suffering from lymphopathies.
  • Such immunoglobulins produced in lymphopathies are monoclonal in origin and result from pathogenic mutations at the genomic level. They have apparently no antigen binding site.
  • the two heavy polypeptide chains of these immunoglobulins can be linked by a hinge region according to the definition of Roitt et al.
  • immunoglobulins corresponding to the above-defined molecules are capable of acting as antibodies.
  • the antigen binding site(s) of the immunoglobulins of the invention are located in the variable region of the heavy chain.
  • each heavy polypeptide chain contains one antigen binding site on its variable region, and these sites correspond to the same amino-acid sequence.
  • the immunoglobulins are characterized in that their heavy polypeptide chains contain a variable region (V HH ) and a constant region (C H ) according to the definition of Roitt et al, but are devoid of the first domain of their constant region. This first domain of the constant region is called C H 1.
  • immunoglobulins having no C H 1 domain are such that the variable region of their chains is directly linked to the hinge region at the C-terminal part of the variable region.
  • the immunoglobulins of the type described hereabove can comprise type G immunoglobulins and especially immunoglobulins which are defined as immunoglobulins of class 2 (IgG2) or immunoglobulins of class 3 (IgG3).
  • Fc and pFc on the one hand, Fc' and pFc' on the other hand corresponding respectively to the papain and pepsin digestion fragments are maintained.
  • Fab F(ab) 2 F(ab') 2 Fabc, Fd and Fv are no longer applicable in their original sense as these fragments have either a light chain, the variable part of the light chain or the C H 1 domain.
  • the fragments obtained by papain digestion and composed of the V HH domain and the hinge region will be called FV HH h or F(V HH h) 2 depending upon whether or not they remain linked by the disulphide bonds.
  • immunoglobulins replying to the hereabove given definitions can be originating from animals especially from animals of the camelid family.
  • the inventors have found out that the heavy-chain immunoglobulins which are present in camelids are not associated with a pathological situation which would induce the production of abnormal antibodies with respect to the four-chain immunoglobulins.
  • camelids for example Lama Paccos, Lama Glama, and Lama Vicugna
  • Lama Paccos, Lama Glama, and Lama Vicugna the inventors have shown that the immunoglobulins of the invention, which are devoid of light polypeptide chains are found in all species.
  • molecular weight of these immunoglobulins can be from approximately 43 kd to approximately 47 kd, in particular 45 kd.
  • the heavy-chain immunoglobulins of the invention are secreted in blood of camelids.
  • Immunoglobulins according to this particular embodiment of the invention are obtainable by purification from serum of camelids and a process for the purification is described in details in the examples.
  • the invention relates to immunoglobulins which are not in their natural biological environment.
  • immunoglobulin IgG2 as obtainable by purification from the serum of camelids can be characterized in that:
  • immunoglobulins corresponding to IgG3, as obtainable by purification from the serum of Camelids is characterized in that the immunoglobulin:
  • the immunoglobulins of the invention which are devoid of light chains, nevertheless comprise on their heavy chains a constant region and a variable region.
  • the constant region comprises different domains.
  • variable region of immunoglobulins of the invention comprises frameworks (FW) and complementarity determining regions (CDR), especially 4 frameworks and 3 complementarity regions. It is distinguished from the four-chain immunoglobulins especially by the fact that this variable region can itself contain an antigen binding site or several, without contribution of the variable region of a light chain which is absent.
  • amino-acid sequences of frameworks 1 and 4 comprise among others respectively amino-acid sequences which can be selected from the following:
  • the immunoglobulins of the invention are preferably devoid of the totality of their C H 1 domain.
  • Such immunoglobulins comprise C H 2 and C H 3 domains in the C-terminal region with respect to the hinge region.
  • the constant region of the immunoglobulins comprises C H 2 and C H 3 domains comprising an amino-acid sequence selected from the following:
  • the hinge region of the immunoglobulins of the invention can present variable lengths.
  • these immunoglobulins act as antibodies, the length of the hinge region will participate to the determination of the distance separating the antigen binding sites.
  • an immunoglobulin according to the invention is characterized in that its hinge region comprises from 0 to 50 amino-acids.
  • the short hinge region corresponds to an IgG3 molecule and the long hinge sequence corresponds to an IgG2 molecule.
  • V HH derived from heavy chain immunoglobulins or V HH libraries corresponding to the heavy chain immunoglobulins can be distinguished from V HH cloning of four-chain model immunoglobulins on the basis of sequence features characterizing heavy chain immunoglobulins.
  • the camel heavy--chain immunoglobulin V HH region shows a number of differences with the V HH regions derived from 4-chain immunoglobulins from all species examined. At the levels of the residues involved in the V HH /V L interactions, an important difference is noted at the level of position 45 (FW) which is practically always leucine in the 4-chain immunoglobulins (98%), the other amino acids at this position being proline (1%) or glutamine (1%).
  • leucine at position 45 is only found once. It could originate from a four-chain immunoglobulin. In the other cases, it is replaced by arginine, cysteine or glutamic acid residue. The presence of charged amino acids at this position should contribute to making the V HH more soluble.
  • a second feature specific of the camelid V HH domain is the frequent presence of a cysteine in the CDR 3 region associated with a cysteine in the CDR 1 position 31 or 33 or FW 2 region at position 45.
  • the possibility of establishing a disulphide bond between the CDR 3 region and the rest of the variable domain would contribute to the stability and positioning of the binding site.
  • DAW single pathogenic myeloma protein
  • the heavy-chain immunoglobulins of the invention have further the particular advantage of being not sticky. Accordingly these immunoglobulins being present in the serum, aggregate much less than isolated heavy chains of a four-chain immunoglobulins.
  • the immunoglobulins of the invention are soluble to a concentration above 0.5 mg/ml, preferably above 1 mg/ml and more advantageously above 2 mg/ml.
  • immunoglobulins further bear an extensive antigen binding repertoire and undergo affinity and specificity maturation in vivo. Accordingly they allow the isolation and the preparation of antibodies having defined specificity, regarding determined antigens.
  • immunoglobulins of the invention can be modified and especially humanized. Especially it is possible to replace all or part of the constant region of these immunoglobulins by all or part of a constant region of a human antibody.
  • the C H 2 and/or C H 3 domains of the immunoglobulin could be replaced by the C H 2 and/or C H 3 domains of the IgG ⁇ 3 human immunoglobulin.
  • variable sequence namely one or more of the framework residues which do not intervene in the binding site by human framework residues, or by a part of a human antibody.
  • V HH regions could be introduced into the V H or V L regions derived from four-chain immunoglobulins with for instance the aim of achieving greater solubility of the immunoglobulins.
  • the invention further relates to a fragment of an immunoglobulin which has been described hereabove and especially to a fragment selected from the following group:
  • fragments obtained by enzymatic digestion of the immunoglobulins of the invention especially those obtained by partial digestion with papain leading to the Fc fragment (constant fragment) and leading to FV HH h fragment (containing the antigen binding sites of the heavy chains) or its dimer F(V HH h) 2 , or a fragment obtained by further digestion with papain of the Fc fragment, leading to the pFc fragment corresponding to the C-terminal part of the Fc fragment,
  • variable region of the immunoglobulin or the complete variable region, especially a fragment corresponding to the isolated V HH domains or to the V HH dimers linked to the hinge disulphide,
  • the invention also relates to a fragment comprising a repeated sequence, Pro-X which repeated sequence contains at least 3 repeats of Pro-X, X being any amino-acid and preferably Gln (glutamine), Lys (lysine) or Glu (acide glutamique); a particular repeated fragment is composed of a 12-fold repeat of the sequence Pro-X.
  • Such a fragment can be advantageously used as a link between different types of molecules.
  • the amino-acids of the Pro-X sequence are chosen among any natural or non natural amino-acids.
  • the fragments can be obtained by enzymatic degradation of the immunoglobulins. They can also be obtained by expression in cells or organisms, of nucleotide sequence coding for the immunoglobulins, or they can be chemically synthesized.
  • the invention also relates to anti-idiotypes antibodies belonging to the heavy chain immunoglobulin classes.
  • anti-idiotypes can be produced against human or animal idiotypes.
  • a property of these anti-idiotypes is that they can be used as idiotypic vaccines, in particular for vaccination against glycoproteins or glycolipids and where the carbohydrate determines the epitope.
  • the invention also relates to anti-idiotypes capable of recognizing idiotypes of heavy-chain immunoglobulins.
  • anti-idiotype antibodies can be either syngeneic antibodies or allogenic or xenogeneic antibodies.
  • the invention also concerns nucleotide sequences coding for all or part of a protein which amino-acid sequence comprises a peptide sequence selected from the following:
  • nucleotide sequences can be deduced from the amino-acid sequences taking into account the deneneracy of the genetic code. They can be synthesized or isolated from cells producing immunoglobulins of the invention.
  • RNA especially mRNA sequences corresponding to these DNA sequences, and also corresponding cDNA sequences.
  • nucleotide sequences of the invention can further be used for the preparation of primers appropriate for the detection in cells or screening of DNA or cDNA libraries to isolate nucleotide sequences coding for immunoglobulins of the invention.
  • nucleotide sequences can be used for the preparation of recombinant vectors and the expression of these sequences contained in the vectors by host cells especially prokaryotic cells like bacteria or also eukaryotic cells and for example CHO cells, insect cells, simian cells like Vero cells, or any other mammalian cells.
  • host cells especially prokaryotic cells like bacteria or also eukaryotic cells and for example CHO cells, insect cells, simian cells like Vero cells, or any other mammalian cells.
  • the immunoglobulins of the invention are devoid of light chains permits to secrete them in eukaryotic cells since there is no need to have recourse to the step consisting in the formation of the BIP protein which is required in the four-chain immunoglobulins.
  • the inadequacies of the known methods for producing monoclonal antibodies or immunoglobulins by recombinant DNA technology comes from the necessity in the vast majority of cases to clone simultaneously the V H and V L domains corresponding to the specific binding site of 4 chain immunoglobulins.
  • the animals and especially camelids which produce heavy-chain immunoglobulins according to the invention, and possibly other vertebrate species are capable of producing heavy-chain immunoglobulins of which the binding site is located exclusively in the V HH domain.
  • the camelid heavy-chain immunoglobulins have undergone extensive maturation in vivo.
  • V region has naturally evolved to function in absence of the V L . They are therefore ideal for producing monoclonal antibodies by recombinant DNA technology. As the obtention of specific antigen binding clones does not depend on a stochastic process necessitating a very large number of recombinant cells, this allows also a much more extensive examination of the repertoire.
  • the invention thus provides libraries which can be generated in a way which includes part of the hinge sequence, the identification is simple as the hinge is directly attached to the V HH domain.
  • PCR primers are located in the promoter, leader or framework sequences of the V HH for the 5' primer and in the hinge, CH 2 , CH 3 , 3' untranslated region or polyA tail for the 3' primer.
  • a size selection of amplified material allows the construction of a library limited to heavy chain immunoglobulins.
  • the following 3' primer in which a KpnI site has been constructed and which corresponds to amino-acids 313 to 319 is used in conjunction with mouse V HH primers described by Sestry et al and containing a Xho site
  • These primers yield a library of camelid heavy chain immunoglobulins comprising the V HH region (related to mouse or human subgroup III), the hinge and a section of CH 2 .
  • the cDNA is polyadenylated at its 5' end and the mouse specific V HH primers are replaced by a poly T primer with an inbuilt XhoI site, at the level of nucleotide 12.
  • This method generates a library containing all subgroups of immunoglobulins.
  • a Sac site is present immediately after the hinge. This site allows the grafting of the sequence coding for the V HH and the hinge onto the Fc region of other immunoglobulins, in particular the human IgG 1 and IgG 3 which have the same amino acid sequence at this site (Glu 246 Leu 247 )
  • the invention contemplates a cDNA library composed of nucleotide sequences coding for a heavy-chain immunoglobulin, such as obtained by performing the following steps:
  • lymphoid cells especially periferal, lymphocytes, spleen cells, lymph nodes or another lyphoid tissue from a healthy animal, especially selected among the Camelids, in order to separate the lymphoid cells,
  • step c) contacting the cDNA of step c) with 5' primers corresponding to mouse V H domain of four-chain immunoglobulins, which primer contains a determined restriction site, for example an XhoI site and with 3' primers corresponding to the N-terminal part of a C H 2 domain containing a KpnI site,
  • This cloning gives rise to clones containing DNA sequences including the sequence coding for the hinge. It thus permits the characterization of the subclass of the immunoglobulin and the SacI site useful for grafting the FV HH h to the Fc region.
  • the recovery of the sequences coding for the heavy-chain inmunoglobulins can also be achieved by the selection of clones containing DNA sequences having a size compatible with the lack of the C H 1 domain.
  • oligonucleotide degenerated primers which sequences are capable of coding for the hinge region and N-terminal V HH domain of an immunoglobulin, the primers being capable of hybridizing with the cDNA and capable of initiating the extension of a DNA sequence complementary to the cDNA used as template,
  • the clones can be expressed in several types of expression vectors.
  • clones produced in Bluescript® according to the above described procedure, are recovered by PCR using the same XhoI containing 5' primer and a new 3' primer, corresponding to residues 113-103 in the framework of the immunoglobulins, in which an Spe site has been constructed: TC TTA ACT AGT GAG GAG ACG GTG ACC TG SEQ ID NO:51. This procedure allows the cloning of the V HH in the Xho/Spe site of the Immuno PBS vector.
  • the 3' end of the gene is not in phase with the identification "tag” and the stop codon of the vector.
  • the construct is cut with Spe and the 4 base overhangs are filled in, using the Klenow fragment after which the vector is religated.
  • a further refinement consists in replacing the marker ("tag") with a poly histidine so that metal purification of the cloned V HH can be performed.
  • a Spe/EcoRI double stranded oligonucleotide coding for 6 histidines and a termination codon is first constructed by synthesis of both strands followed by heating and annealing:
  • V HH can equally be detected by using antibodies raised against the dromedary V HH regions. Under laboratory conditions, V HH regions are produced in the Immuno PBS vector in mg amounts per liter.
  • the invention also relates to a DNA library composed of nucleotide sequences coding for a heavy-chain immunoglobulin, such as obtained from cells with rearranged immunoglobulin genes.
  • the library is prepared from cells from an animal previously immunized against a determined antigen. This allows the selection of antibodies having a preselected specificity for the antigen used for immunization.
  • the amplification of the cDNA is not performed prior to the cloning of the cDNA.
  • the heavy-chain of the four-chain immunoglobulins remains sequestered in the cell by a chaperon protein (BIP) until it has combined with a light chain.
  • BIP chaperon protein
  • the binding site for the chaperon protein is the C H 1 domain. As this domain is absent from the heavy chain immunoglobulins, their secretion is independent of the presence of the BIP protein or of the light chain. Moreover the inventors have shown that the obtained immunoglobulins are not sticky and accordingly will not abnormally aggregate.
  • the invention also relates to a process for the preparation of a monoclonal antibody directed against a determined antigen, the antigen binding site of the antibody consisting of heavy polypeptide chains and which antibody is further devoid of light polypeptide chains, which process comprises:
  • immortalizing lymphocytes obtained for example from the peripheral blood of Camelids previously immunized with a determined antigen, with an immortal cell and preferably with myeloma cells, in order to form a hybridoma,
  • the preparation of antibodies can also be performed without a previous immunization of Camelids.
  • antibodies are prepared in vitro and they can be obtained by a process comprising the steps of:
  • the cloning is performed in vectors, especially into plasmids coding for bacterial membrane proteins.
  • Procaryotic cells are then transformed with the above vectors in conditions allowing the expression of antibodies in their membrane.
  • the positive cells are further selected by antigen affinity selection.
  • the heavy chain antibodies which do not contain the C H 1 domain present a distinct advantage in this respect.
  • the C H 1 domain binds to BIP type chaperone proteins present within eukaryotic vectors and the heavy chains are not transported out of the endocytoplasmic reticulum unless light chains are present.
  • efficient cloning of 4-chain immunoglobulins in non mammalian cells such as yeast cells can depend on the properties of the resident BIP type chaperone and can hence be very difficult to achieve.
  • the heavy chain antibodies of the invention which lack the CH 1 domain present a distinctive advantage.
  • the cloning can be performed in yeast either for the production of antibodies or for the modification of the metabolism of the yeast.
  • Yep 52 vector can be used. This vector has the origin of replication (ORI) 2 ⁇ of the yeast together with a selection marker Leu 2.
  • the cloned gene is under the control of gal1 promoter and accordingly is inducible by galactose. Moreover, the expression can be repressed by glucose which allows the obtention of very high concentration of cells before the induction.
  • metabolic modulation which can be obtained by antibodies and proposed for the yeast, one can site the cloning of antibodies directed against cyclins, that is proteins involved in the regulation of the cellular cycle of the yeast (TIBS 16 430 J. D. Mc Kinney, N. Heintz 1991).
  • Another example is the introduction by genetic engineering of an antibody directed against CD 28 , which antibody would be inducible (for instance by gall), within the genome of the yeast.
  • the CD 28 is involved at the level of the initiation of cell division, and therefore the expression of antibodies against this molecule would allow an efficient control of multiplication of the cells and the optimization of methods for the production in bioreactors or by means of immobilized cells.
  • the cloning vector is a plasmid or a eukaryotic virus vector and the cells to be transformed are eukaryotic cells, especially yeast cells, mammalian cells for example CHO cells or simian cells such as Vero cells, insect cells, plant cells, or protozoan cells.
  • Particular antibodies according to the invention are directed against the galactosyl ⁇ -1-3-galactose epitope.
  • the immunoglobulins of the invention allow further the preparation of combined products such as the combination of the heavy-chain immunoglobulin or a fragment thereof with a toxin, an enzyme, a drug, a hormone.
  • Another advantageous combination is that one can prepare between a heavy-chain immunoglobulins recognizing an insect gut antigen with a toxin specific for insects such as the toxins of the different serotypes of Bacillus thuringiensis or Bacillus sphaericus. Such a construct cloned into plants can be used to increase the specificity or the host range of existing bacterial toxins.
  • the invention also proposes antibodies having different specificities on each heavy polypeptide chains. These multifunctional, especially bifunctional antibodies could be prepared by combining two heavy chains of immunoglobulins of the invention or one heavy chain of an immunoglobulin of the invention with a fragment of a four-chain model immunoglobulin.
  • the invention also provides hetero-specific antibodies which can be used for the targetting of drugs or any biological substance like hormones.
  • they can be used to selectively target hormones or cytokines to a limited category of cells.
  • examples are a combination of a murine or human antibody raised against interleukin 2 (IL 2 ) and a heavy-chain antibody raised against CD 4 cells. This could be used to reactivate CD 4 cells which have lost their IL 2 receptor.
  • the heavy-chain immunoglobulins of the invention can also be used for the preparation of heterospecific antibodies. These can be achieved either according to the above described method by reduction of the bridges between the different chains and reoxydation, according to the usual techniques, of two antibodies having different specificities, but it can also be achieved by serial cloning of two antibodies for instance in the Immuno pBS vector.
  • a first gene corresponding to the V HH domain comprised between Xho site and a Spe site is prepared as described above.
  • a second gene is then prepared through an analogous way by using as 5' extremity a primer containing a Spe site, and as 3' extremity a primer containing a termination codon and an EcoRI site.
  • the vector is then digested with EcoRI and XhoI and further both V HH genes are digested respectively by Xho/Spe and by Spe/EcoRI.
  • both immunoglobulin genes are serially cloned.
  • the spacing between both genes can be increased by the introduction of addition codons within the 5' SpeI primer.
  • a sequence comprising a repeated sequence Pro-X, X being any amino-acid and preferably Gln, Lys or Glu, especially a fragment composed of at least a 3-fold repeat and preferably of a 12-fold repeat, for coupling proteins to ligand, or for assembling different protein domains.
  • the hinge region or a fragment thereof can also be used for coupling proteins to ligands or for assembling different protein domains.
  • the antibodies according to this invention could be used as reagents for the diagnosis in vitro or by imaging techniques.
  • the immunoglobulins of the invention could be labelled with radio-isotopes, chemical or enzymatic markers or chemiluminescent markers.
  • a label like technetium, especially technitium 99 is advantageous.
  • This label can be used for direct labelling by a coupling procedure with the immunoglobulins or fragments thereof or for indirect labelling after a step of preparation of a complex with the technitium.
  • radioactive labels are for instance indium and especially indium 111, or iodine, especially I 131 , I 125 and I 123 .
  • V HH fragment is a definitive advantage for penetration into tissue.
  • the invention also concerns monoclonal antibodies reacting with anti-idiotypes of the above-described antibodies.
  • the invention also concerns cells or organisms in which heavy-chain immunoglobulins have been cloned.
  • Such cells or organisms can be used for the purpose of producing heavy-chain immunoglobulins having a desired preselected specificity, or corresponding to a particular repertoire. They can also be produced for the purpose of modifying the metabolism of the cell which expresses them.
  • these produced heavy-chain immunoglobulins are used like antisense DNA.
  • Antisense DNA is usually involved in blocking the expression of certain genes such as for instance the variable surface antigen of trypanosomes or other pathogens. Likewise, the production or the activity of certain proteins or enzymes could be inhibited by expressing antibodies against this protein or enzyme within the same cell.
  • the invention also relates to a modified 4-chain immunoglobulin or fragments thereof, the V H regions of which has been partialy replaced by specific sequences or amino acids of heavy chain immunoglobulins, especially by sequences of the V HH domain.
  • a particular modified V H domain of a four-chain immunoglobulin is characterized in that the leucine, proline or glutamine in position 45 of the V H regions has been replaced by other amino acids and preferably by arginine, glutamic acid or cysteine.
  • a further modified V H or V L domain of a four-chain immunoglobulin is characterized by linking of CDR loops together or to FW regions by the introduction of paired cysteines, the CDR region being selected between the CDR 1 and the CDR 3 , the FW region being the FW 2 region, and especially in which one of the cysteines introduced is in position 31, 33 of the CDR 1 or 45 of FW 2 and the other in CDR 3 .
  • paired cysteines is such that the CDR 3 loop is linked to the FW2 or CDR1 domain and more especially the cysteine of the CDR3 of the V H is linked to a cysteine in position 31, 33 of the CDR 1 or in position 45 of FW 2 .
  • plant cells can be modified by the heavy-chain immunoglobulins according to the invention, in order that they acquire new properties or increased properties.
  • the heavy-chain immunoglobulins of the invention can be used for gene therapy of cancer for instance by using antibodies directed against proteins present on the tumor cells.
  • the expression of one or two V HH genes can be obtained by using vectors derived from parvo or adeno viruses.
  • the parvo viruses are characterized by the fact that they are devoid of pathogenicity or almost not pathogenic for normal human cells and by the fact that they are capable of easily multiplying in cancer cells (Russel S. J. 1990, Immunol. Today II. 196-200).
  • the heavy-chain immunoglobulins are for instance cloned within HindIII/XbaI sites of the infectious plasmid of the murine MVM virus (pMM984). (Merchlinsky et al, 1983, J. Virol. 47, 227-232) and then placed under the control of the MVM38 promoter.
  • the gene of the V HH domain is amplified by PCR by using a 5' primer containing an initiation codon and a HindIII site, the 3' primer containing a termination codon and a XbaI site.
  • This construct is then inserted between positions 2650 (HindIII) and 4067 (XbaI) within the plasmid.
  • the efficiency of the cloning can be checked by transfection.
  • the vector containing the antibody is then introduced in permissive cells (NB-E) by transfection.
  • the cells are recovered after two days and the presence of V HH regions is determined with an ELISA assay by using rabbit antiserum reacting with the V HH part.
  • the invention further allows the preparation of catalytic antibodies through different ways.
  • the production of antibodies directed against components mimicking activated states of substrates permits to obtain antibodies having a catalytic function.
  • Another way to obtain such antibodies consists in performing a random mutagenesis in clones of antibodies for example by PCR, in introducing abnormal bases during the amplification of clones. These amplified fragments obtained by PCR are then introduced within an appropriate vector for cloning. Their expression at the surface of the bacteria permits the detection by the substrate of clones having the enzymatic activity.
  • V HH of the heavy chain immunoglobulins of the invention is the fact that they are sufficiently soluble.
  • the heavy chain immunoglobulins of the invention can further be produced in plant cells, especially in transgenics plants.
  • the heavy chain immunoglobulins can be produced in plants using the pMon530 plasmid (Roger et al. Meth Enzym 153 1566 1987) constitutive plant expression vector as has been described for classical four chain antibodies (Hiat et al. Nature 342 76-78, 1989) once again using the appropriate PCR primers as described above, to generate a DNA fragment in the right phase.
  • FIG. (A) shows, after reduction, the SDS-PAGE protein profile of the adsorbed and non adsorbed fractions of Camelus dromedarius serum.
  • the fraction adsorbed on Protein A and eluted with NaCl 0.15 M acetic acid 0.58% show upon reduction (lane c) three heavy chain components of respectively 50, 46 and 43 Kd and light chain (rabbit IgG in lane a).
  • the fractions adsorbed on a Protein G Sepharose (Pharmacia) derivative which has been engineered to delete the albumin binding region (lane e) and eluted with 0.1 M gly HCl pH 2.7 lacks the 46 Kd heavy chain which is recovered in the non adsorbed fraction (lane f). None of these components are present in the fraction non adsorbed on Protein A (lane d), lane b contains the molecular weight markers.
  • FIGS. (B) and (C) By differential elution, immunoglobulin fractions containing the 50 and 43 Kd heavy chain can be separated.
  • 5 ml of C. dromadarius serum is adsorbed onto a 5 ml Protein G sepharose column and the column is extensively washed with 20 mM phosphate buffer, pH 7.0.
  • pH 3.5 buffer (0.15 M NaCl, 0.58% acetic acid)
  • a 100 Kd component is eluted which upon reduction yields a 43 Kd heavy chain, (lane 1).
  • a second immunoglobulin component of 170 Kd can be eluted with pH 2.7 buffer (0.1 M glycine HC). This fraction upon reduction yields a 50 Kd heavy chain and a board light chain band (lane 2). The fraction non adsorbed on Protein G is then brought on a 5 ml Protein A Sepharose column. After washing and elution with pH 3.5 buffer (0.15 M NaCl, 0.58% acetic acid) a third immunoglobulin of 100 Kd is obtained which consists solely of 46 Kd heavy chains (lane 3).
  • FIG. (A) In all species examined the unreduced fractions FIG. (A) contain in addition to molecules of approximately 170 Kd also smaller major components of approximately 100 Kd. In the reduced sample FIG. (B) the constituant heavy and light chains are detected. In all species a heavy chain component (marked by an asterisk *) is present in the material eluted from the Protein A but absent in the material eluted from the Protein G.
  • IgG 1 , IgG 2 and IgG 3 were prepared from serum obtained from healthy or Trypanosama evansi infected Camelus dromedarius (CATT titer 1/160 (3) and analysed by radioimmunopreci- pitation or Western Blotting for anti trypanosome activity
  • FIG. (A) 35 S methionine labelled Trypanosome evansi antigens lysate (500.000 counts) was added to Eppendorf tubes containing 10 ⁇ l of serum or, 20 ⁇ g of IgG 1 , IgG 2 or IgG 3 in 200 ⁇ l of pH 8.3 immunoprecipitation buffer containing 0.1 M TLCK as proteinase inhibitor and slowly rotated at 4° C. during one hour. The tubes were then supplemented with 10 mg of Protein A Sepharose suspended in 200 ⁇ l of the same pH 8.3 buffer and incubated at 4° C. for an additional hour.
  • each pellet was resuspended in 75 ⁇ l SDS-PAGE sample solution containing DTT and heated for 3 min. at 100° C. After centrifugation in an Eppendorf minifuge at 15000 rpm for 30 s, 5 ⁇ l of the supernatant was saved for radioactivity determination and the reminder analysed by SDS-PAGE and fluorography. The counts/5 ⁇ l sample are inscribed on for each line.
  • FIG. (B) 20 ⁇ g of IgG 1 , IgG 2 and IgG 3 from healthy and trypanosome infected animals were separated by SDS-PAGE without prior reduction or heating. The separated samples were then electro transferred to a nitrocellulose membrane, one part of the membrane was stained with Ponceau Red to localise the protein material and the reminder incubated with 1% ovalbumin in TST buffer (Tris 10 mM, NaCl 150 mM, Tween 0.05%) to block protein binding sites.
  • TST buffer Tris 10 mM, NaCl 150 mM, Tween 0.056%
  • the membrane was extensively washed with TST buffer and incubated for 2 hours with 35 S-labelled trypanosome antigen. After extensive washing, the membrane was dried and analysed by autoradiography. To avoid background and unspecific binding, the labelled trypanosome lysate was filtered through a 45 ⁇ millipore filter and incubated with healthy camel immunoglobulin and ovalbumin adsorbed on a nitrocellulose membrane.
  • Purified IgG3 of the camel, by affinity chromatography on Protein A Sepharose are partially digested with papain and separated on Protein A sepharose.
  • the 100 Kd fraction is totally devoid of light chains and appears to be solely composed of heavy chains which after reduction have on apparent MW of 43 Kd (FIG. 1C).
  • the fraction which does not bind to Protein G can be affinity purified and eluted from a Protein A column as a second 100 Kd component which after reduction appears to be composed solely of 46 Kd heavy chains.
  • the heavy chain immoglobulins devoid of light chains total up to 75% of the molecules binding to Protein A.
  • IgG immunoglobulin binds to Protein A we refer to them as IgG: namely IgG 1 (light chain and heavy chain ⁇ 1 (50 Kd) binding to Protein G, IgG 2 (heavy chain ⁇ 2 (46 Kd) non binding to Protein G and IgG 3 (heavy chain ⁇ 3 (43 Kd) binding to Protein G. There is a possibility that these three sub(classes) can be further subdivided.
  • the corresponding fractions of IgG 1 , IgG 2 , IgG 3 were prepared from the serum of a healthy camel and from the serum of camels with a high antitrypanosome titer, measured by the Card Agglutination Test (3).
  • IgG 1 , IgG 2 and IgG 3 derived from infected camel indicating extensive repertoire heterogeneity and complexity (FIG. 3A) were shown to bind a large number of antigens present in a 35 S methionine labelled trypanosome lysate.
  • Immunoglobulins are characterized by a complex I.E.F. (isoelectric focussing) pattern reflecting their extreme heterogeneity. To determine whether the two heavy chains constituting the IgG 2 and IgG 3 are identical or not, the isoelectric focussing (I.E.F.) pattern were observed before and after chain separation by reduction and alkylation using iodoacetamide as alkylating agent.
  • I.E.F. isoelectric focussing
  • the monomers resulting from the reduction and alkylation of a heavy chain homodimer will have practically the same isolectric point as the dimer, whereas if they are derived from a heavy chain heterodimer, the monomers will in most cases differ sufficiently in isoelectric point to generate a different pattern in I.E.F.
  • I.E.F. pattern of IgG 1 is completely modified after reduction as the isoelectric point of each molecule is determined by the combination of the isoelectric points of the light and heavy chains which after separation will each migrate to a different position.
  • isolated heavy chain from mammalian immunoglobulins tend to aggregate considerably but are only solubilized by light chains (8, 9) which bind to the C H 1 domain of the heavy chain.
  • camelid ⁇ 2 and ⁇ 3 chains are considerably shorter than the normal mammalian ⁇ chain. This would suggest that deletions have occurred in the C H 1 domain. Differences in sizes of the ⁇ 2 and ⁇ 3 immunoglobulins of old and new world camelids suggests that deletions occurred in several evolutionary steps especially in the C H 1 domain.
  • the strategy followed for investigating the heavy chain immunoglobulin primary structure is a combination of protein and cDNA sequencing; the protein sequencing is necessary to identify sequence streches characteristic of each immunoglobulin.
  • the N-terminal of the immunoglobulin being derived from the heavy chain variable region repertoire only yields information on the V HH subgroups (variable region of the heavy chain) and cannot be used for class or subclass identification. This means that sequence data had to be obtained from internal enzymatic or chemical cleavage sites.
  • the IgG3 of the camel (Camelus dromedarius) purified by affinity chromatography on Protein A Sepharose were partially digested with papain and the digest was separated on Protein A Sepharose into binding and non binding fractions. These fractions were analysed by SDS PAGE under reducing and non reducing conditions (FIG. 4A and B).
  • the bound fraction contained two components, one of 28 Kd and one of 14.4 Kd, in addition to uncleaved or partially cleaved material. They were well separated by gel electrophoresis (from preparative 19% SDS-PAGE gels) under non reducing conditions and were further purified by electroelution (in 50 nM amonium bicarbonate, 0.1% (w/v) SDS using a BioRad electro-eluter). After lyophilization of these electroeluted fractions, the remaining SDS was eliminated by precipitating the protein by the addition of 90% ethanol, mixing and incubating the mixture overnight at -20° C. (14). The precipitated protein was collected in a pellet by centrifuging (15000 rpm, 5 min) and was used for protein sequencing.
  • N-terminal sequencing was performed using the automated Edman chemistry of an Applied Biosystem 477A pulsed liquid protein sequencer.
  • Amino acids were identified as their phenylthiohydantoin (PTH) derivatives using an Applied Biosystem 120 PTH analyser. All chemical and reagents were purchased from Applied Biosystems. Analysis of the chromatographic data was performed using Applied Biosystems software version 1.61. In every case the computer aided sequence analysis was cofirmed by direct inspection of the chromatograms from the PTH analyser.
  • Samples for protein sequencing were dissolved in either 50% (v/v) trifluoroacetic acid(TFA) (28 Kd fragment) or 100% TFA (14 Kd fragment).
  • Samples of dissolved protein equivalent to 2000 pmol (28 Kd fragment) or 500 pmol (14 Kd fragment) were applied to TFA-treated glass fibre discs.
  • the glass fibre discs were coated with BioBrene (3 mg) and precycled once before use.
  • N-terminal sequencing of the 28 Kd fragment yields a sequence homologous to the N-terminal part of ⁇ C H 2 domain and hence to the N-terminal end of the Fc fragment.
  • the N-terminal sequence of the 14.4 Kd fragment corresponds to the last lysine of a ⁇ C H 2 and the N-terminal end of a ⁇ C H 3 domain (Table 1).
  • the molecular weight (MW) of the papain fragments and the identification of their N-terminal sequences led us to conclude that the C H 2 and C H 3 domains of the ⁇ 3 heavy chains are normal in size and that the deletion must occur either in the C H 1 or in the V HH domain to generate the shorted ⁇ 3 chain.
  • the fractions which do not bind to Protein A Sepharose contain two bands of 34 and 17 Kd which are more diffuse is SDS PAGE indicating that they originate from the variable N-terminal part of the molecule (FIG. 4A and B).
  • the protein sequence data can be used to construct degenerate oligonucleotide primers allowing PCR amplification of cDNA or genomic DNA.
  • cDNA synthesis is obtained using 1 ⁇ g mRNA template, an oligodT primer and reverse transcriptase (BOERHINGER MAN). Second strand cDNA is obtained using RNAse H and E coli DNA polymerase I according to the condition given by the supplier.
  • PCR products were checked on a 1.2% (w/v) agarose gel. Cleaning up of the PCR products included a phenol-chloroform extractio followed by further purification by HPLC (GEN-PAC FAX column, Waters) and finally by using the MERMAID or GENECLEAN II kit, BIO 101, Inc) as appropriate. After these purification steps, the amplified cDNA was then digested with EcoRI and KpnI for series #56 clones and with XhoI and KpnI for series #72 clones. A final phenol-chloroform extraction preceded the ligation into pUC 18 (series #56 clones) or into pBluescript® (series #72 clones).
  • Clones corresponding to two different sets of C H 2 protein sequences were obtained.
  • a first set of sequences (#72/41) had a N-terminal C H 2 region identical to the one obtained by protein sequencing of the 28 Kd papain fragments of the ⁇ 3 heavy chain, a short hinge region containing 3 cysteines and a variable region corresponding to the framework (FR4) residues encoded by the J minigenes adjoining the hinge.
  • the C H 1 domain is entirely lacking.
  • This cDNA corresponds to the ⁇ 3 chain (Table 4).
  • the sequence corresponding to the C H 3 and the remaining part of the C H 2 was obtained by PCR of the cDNA using as KpnI primer a poly T in which a KpnI restriction site had been inserted at the 5' end.
  • the total sequence of the ⁇ 3 chain corresponds to a molecular weight (MW) which is in good agreement with the data obtained from SDS PAGE electrophoresis.
  • This ⁇ 3 chain presents similarities with other ⁇ chains except that it lacks the C H 1 domain, the V HH domain being adjacent to the hinge.
  • cysteines could be probably responsible for holding the two ⁇ 3 chains together.
  • Papain can cleave the molecule on each side of the hinge disulfides and also between C H 2 and C H 3. Under non reducing conditions the V HH domains of IgG3 can be isolated as disulfide linked dimer or as monomer depending on the site of papain cleavage.
  • a second set of clones #72/29 had a slightly different sequence for the C H 2 and was characterized by a very long hinge immediately preceded by the variable domain. This hinge region has 3 cysteines at its C-terminal end in a sequence homologeous to the ⁇ 3 hinge.
  • Such second set of clones could represent the IgG2 subclass.
  • a few clones such as #72/1 however show minor differences. For instance in the case of clones #72/1 two nucleotide differences are detected.
  • V HH regions cDNA's have now been totally or partially sequenced with the exception of a short stretch at the N-terminal end which is primer derived.
  • the secretion of immunoglobulin heavy chains composing four-chain model immunoglobulins does not occur under normal conditions.
  • a chaperoning protein, the heavy chain binding protein, or BIP protein prevents heavy chains from being secreted. It is only when the light chain dispplaces the BIP protein in the endoplasmatic reticulum that secretion can occur (13).
  • the heavy chain dimer found in the serum of human or mice with the so-called "heavy chain disease” lack the C H 1 domains thought to harbour the BIP site (14). In the absence of thi domain the BIP protein can no longer bind and prevent the transport of the heavy chains.
  • camels of a IgG1 class composed of heavy and light chains making up between 25% and 50% of the total IgG molecules also raises the problem as to how maturation and class switching occurs and what the role of the light chain is.
  • the camelid light chain appears unusually large and heterogeneous when examined in SDS PAGE.
  • the largest dimension of an isolated domain is 40 ⁇ and the maximum attainable span between binding sites of a conventional IgG with C H 1 and V HH will be of the order of 160 ⁇ (2V HH +2C H 1)(19).
  • the deletion of C H 1 domain in the two types of heavy chain antibodies devoid of light chains, already sequenced has, as a result, a modification of this maximum span (FIG. 6).
  • the extreme distance between the extremities of the V HH regions will be of the order of 80 ⁇ (2V HH ). This could be a severe limitation for agglutinating or cross linking.
  • the single V HH domain could also probably allow considerably rotational freedom of the binding site versus the Fc domain.
  • the clones can be expressed in several types of expression vectors.
  • clones produced in Bluescript® according to the above described procedure, have been recovered by PCR using the same XhoI containing 5' primer and a new 3' primer, corresponding to residues 113-103 in the framework of the immunoglobulins, in which an Spe site has been constructed: TC TTA ACT AGT GAG GAG ACG GTG ACC TG SEQ ID NO:51. This procedure allowed the cloning of the V HH in the Xho/Spe site of the Immuno PBS vector.
  • the 3' end of the gene was not in phase with the identification "tag” and the stop codon of the vector.
  • the construct was cut with Spe and the 4 base overhangs were filled in, using the Klenow fragment after which the vector was religated.
  • the expression vector plasmid ipBS (immunopBS) (Stratacyte) contains a pel B leader sequence which is used for immunoglobulin chain expression in E.coli under the promotor pLAC control, a ribosome binding site, and stop codons. In addition, it contains a sequence for a c-terminal decapeptide tag.
  • E.coli JM101 harboring the ipBS-V HH 21 plasmid was grown in 1 l of TB medium with 100 ⁇ g/ml ampicillin and 0.1% glucose at 32° C. Expression was induced by the addition of 1 mM IPTG (final concentration) at an OD 550 of 1.0. After overnight induction at 28° C., the cells were harvested by centrifugation at 4.000 g for 10 min (4° C.) and resuspended in 10 ml TES buffer (0.2 M Tris-HCL pH 8.0, 0.5 mM EDTA, 0.5 M sucrose). The suspension was kept on ice for 2 hours.
  • Periplasmic proteins were removed by osmotic shock by addition of 20 ml TES buffer diluted 1:4 v/v with water, kept on ice for one hour and subsequently centrifugated at 12.000 g for 30 min. at 4° C.
  • the supernatant periplasmic fraction was dialysed against Tris-HCl pH 8.8, NaCl 50 mM, applied on a fast Q Sepharose flow (Pharmacia) column, washed with the above buffer prior and eluted with a linear gradient of 50 mM to 1 M NaCl in buffer.
  • V HH protein Fractions containing the V HH protein were further purified on a Superdex 75 column (Pharmacia) equilibrated with PBS buffer (0.01 M phosphate pH 7.2, 0.15 M NaCl). The yield of purified V HH protein varies from 2 to 5 mg/l cell culture.
  • FIG. 8 shows: C,D:fractions from fast S Sepharose column chromatography (C:Eluted at 650 mM NaCl D:Eluted at 700 mM NaCl) E,F:fractions from Superdex 75 column chromatography.
  • the major impurity is eliminated by ionexchange chromatography and the bulk of the remaining impurities are eliminated by gel filtration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US08/468,739 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains Expired - Lifetime US6015695A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/468,739 US6015695A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP92402326 1992-08-21
EP92402326A EP0584421A1 (en) 1992-08-21 1992-08-21 Immunoglobulins devoid of light chains
EP93401310 1993-05-21
EP93401310 1993-05-21
US10694493A 1993-08-17 1993-08-17
US08/468,739 US6015695A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10694493A Division 1992-08-21 1993-08-17

Publications (1)

Publication Number Publication Date
US6015695A true US6015695A (en) 2000-01-18

Family

ID=26132410

Family Applications (5)

Application Number Title Priority Date Filing Date
US08/468,739 Expired - Lifetime US6015695A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains
US08/471,282 Expired - Lifetime US5840526A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains
US08/471,780 Expired - Lifetime US5759808A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains
US08/467,282 Expired - Lifetime US5800988A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains
US08/466,710 Expired - Lifetime US5874541A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains

Family Applications After (4)

Application Number Title Priority Date Filing Date
US08/471,282 Expired - Lifetime US5840526A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains
US08/471,780 Expired - Lifetime US5759808A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains
US08/467,282 Expired - Lifetime US5800988A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains
US08/466,710 Expired - Lifetime US5874541A (en) 1992-08-21 1995-06-06 Immunoglobulins devoid of light chains

Country Status (13)

Country Link
US (5) US6015695A (da)
EP (6) EP0656946B2 (da)
JP (4) JP3444885B2 (da)
AT (5) ATE420178T1 (da)
AU (1) AU701578B2 (da)
CA (1) CA2142331C (da)
DE (6) DE69334305D1 (da)
DK (5) DK1589107T3 (da)
ES (5) ES2325541T3 (da)
FI (3) FI115462B (da)
GR (1) GR3037024T3 (da)
PT (5) PT1498427E (da)
WO (1) WO1994004678A1 (da)

Cited By (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215448A1 (en) * 2001-06-05 2003-11-20 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
US20040052792A1 (en) * 2002-09-18 2004-03-18 Advanced Biotherapy, Inc. Treatment of schizophrenia
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20040086508A1 (en) * 2001-06-05 2004-05-06 Advanced Biotherapy, Inc. Treatment of organ transplant rejection
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
US20050048060A1 (en) * 2002-01-03 2005-03-03 Hilde Revets Immunoconjugates
WO2005044998A2 (en) 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody
US20050136049A1 (en) * 2001-01-17 2005-06-23 Ledbetter Jeffrey A. Binding constructs and methods for use thereof
US20050152902A1 (en) * 2001-06-05 2005-07-14 Advanced Biotherapy, Inc. Treatment of diabetic retinopathy
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US20050202028A1 (en) * 2001-01-17 2005-09-15 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US20060063921A1 (en) * 2002-06-28 2006-03-23 Domantis Limited Ligand
US20060062784A1 (en) * 2004-09-17 2006-03-23 Domantis Limited Compositions monovalent for CD40L binding and methods of use
US20060177445A1 (en) * 2004-08-16 2006-08-10 Boris Skurkovich Treatment of inflammatory skin diseases
US20060194221A1 (en) * 2004-10-12 2006-08-31 Boris Skurkovich Treatment of herpes
US20060246523A1 (en) * 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
US20060246524A1 (en) * 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
US20070059306A1 (en) * 2005-07-25 2007-03-15 Trubion Pharmaceuticals, Inc. B-cell reduction using CD37-specific and CD20-specific binding molecules
US20070083564A1 (en) * 2005-10-07 2007-04-12 Ramacher Mark C Automatic performance statistical comparison between two periods
US20070117153A1 (en) * 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
US20070180542A1 (en) * 2004-04-12 2007-08-02 The Trustees Of The University Of Pennsylvania Culture conditions and growth factors affecting fate determination, self-renewal and expansion of rat spermatogonial stem cells
US20070218063A1 (en) * 2006-03-14 2007-09-20 Boris Skurkovich Method and composition for treatment of renal disease with antibodies and their equivalents
US20080070268A1 (en) * 2006-04-21 2008-03-20 Wyeth Differential expression profiling analysis of cell culture phenotypes and the uses thereof
WO2008063378A2 (en) 2006-11-01 2008-05-29 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
WO2008109410A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
WO2008151081A1 (en) 2007-06-01 2008-12-11 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
US20080305497A1 (en) * 2007-05-23 2008-12-11 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US20090017460A1 (en) * 2007-06-15 2009-01-15 Wyeth Differential expression profiling analysis of cell culture phenotypes and uses thereof
WO2009012181A2 (en) 2007-07-13 2009-01-22 Ventana Medical Systems, Inc. Method of identifying diagnostic reagents
US20090186358A1 (en) * 2007-12-21 2009-07-23 Wyeth Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
US20100034820A1 (en) * 2001-01-17 2010-02-11 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
EP2198882A2 (en) 2001-01-12 2010-06-23 Novartis Vaccines and Diagnostics, Inc. Nucleic acid mucosal immunization
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20100189919A1 (en) * 2009-01-27 2010-07-29 Xerox Corporation Imaging System And Process Using Monoclonal Antibodies
US20100226920A1 (en) * 2006-03-27 2010-09-09 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
US20100233734A1 (en) * 2009-03-16 2010-09-16 Roderick Nicholas Hobbs Passivation of surfaces after ligand coupling
US20110033483A1 (en) * 2006-06-12 2011-02-10 Trubion Pharmaceuticals Inc. Single-chain multivalent binding proteins with effector function
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
WO2011072266A2 (en) 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
US20110145937A1 (en) * 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice That Make Heavy Chain Antibodies
US20110171208A1 (en) * 2008-04-11 2011-07-14 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2011106583A1 (en) 2010-02-26 2011-09-01 Ventana Medical Systems, Inc. Polytag probes
WO2011128701A2 (en) 2010-04-16 2011-10-20 Imperial Innovations Limited Cancer methods
WO2011133625A1 (en) 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
WO2011139907A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
WO2011140267A2 (en) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
WO2011139854A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
WO2012003476A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
WO2012024185A1 (en) 2010-08-16 2012-02-23 Ventana Medical Systems, Inc. Substrates for chromogenic detection and methods of use in detection assays and kits
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
WO2012089814A1 (en) 2010-12-30 2012-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
WO2012092322A1 (en) 2010-12-30 2012-07-05 Ventana Medical Systems, Inc. Enhanced deposition of chromogens utilizing pyrimidine analogs
EP2495307A1 (en) 2006-07-13 2012-09-05 Wyeth LLC Production of glycoproteins
WO2012123387A1 (en) 2011-03-14 2012-09-20 F. Hoffmann-La Roche Ag A method of analyzing chromosomal translocations and a system therefore
WO2012166906A1 (en) 2011-05-31 2012-12-06 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
WO2013033073A1 (en) 2011-08-31 2013-03-07 Ventana Medical Systems, Inc. Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
WO2013034933A1 (en) 2011-09-08 2013-03-14 Imperial Innovations Limited Anti ddr1 antibodies, their uses and methods identifying them
WO2013041901A1 (en) 2011-09-20 2013-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing single domain antibody microarrays
WO2013079973A1 (en) 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
WO2013079606A1 (en) 2011-12-01 2013-06-06 Ventana Medical Systems, Inc. Automated dual stain of mirna and protein targets
WO2013108126A2 (en) 2012-01-16 2013-07-25 University Of Oslo Methyltransferases and uses thereof
WO2013148498A1 (en) 2012-03-27 2013-10-03 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
EP2700651A1 (en) 2008-07-18 2014-02-26 Bristol-Myers Squibb Company Compositions monovalent for CD28 binding and methods of use
US8703490B2 (en) 2008-06-05 2014-04-22 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
WO2014143155A1 (en) 2013-03-12 2014-09-18 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2902494A1 (en) 2007-11-09 2015-08-05 The Salk Institute for Biological Studies Use of tam receptor inhibitors as antimicrobials
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
WO2016054522A1 (en) 2014-10-03 2016-04-07 Ntercept, Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
WO2016116760A2 (en) 2015-01-21 2016-07-28 Cancer Research Technology Limited Inhibitors
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
WO2016166110A1 (en) 2015-04-13 2016-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
EP3184121A2 (en) 2012-07-25 2017-06-28 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
US9778265B2 (en) 2015-04-16 2017-10-03 The United States Of America, As Represented By The Secretary Of The Navy Charged peptide appendage to facilitate oriented protein covalent immobilization
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
US9920115B2 (en) 2016-05-20 2018-03-20 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
WO2018078083A1 (en) 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
US9982247B2 (en) 2012-07-19 2018-05-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for purifying transgenic factor VII/VIIA
WO2018136823A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
WO2018141753A1 (en) 2017-01-31 2018-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating squamous cell carcinomas
US10066016B2 (en) 2016-05-20 2018-09-04 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
US10202441B2 (en) 2013-12-26 2019-02-12 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019197683A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
WO2020016160A1 (en) 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2020049130A1 (en) 2018-09-05 2020-03-12 Valerie Nicholas Carl Kristoffer Methods
WO2020089273A1 (en) 2018-10-31 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating t-helper type 2 mediated disease
WO2020148349A1 (en) 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
US10787522B2 (en) 2014-03-21 2020-09-29 Regeneron Pharmaceuticals, Inc. VL antigen binding proteins exhibiting distinct binding characteristics
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2020208082A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020229546A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
WO2020229648A1 (en) 2019-05-16 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat type 2 inflammation or mast-cell dependent disease
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
US10849973B2 (en) 2016-11-23 2020-12-01 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2020245160A1 (en) 2019-06-03 2020-12-10 Fenomark Diagnostics Ab Medical uses, methods and uses
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
US10927180B2 (en) 2017-10-13 2021-02-23 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
WO2021046159A1 (en) 2019-09-04 2021-03-11 Genentech, Inc. Cd8 binding agents and uses thereof
WO2021044012A1 (en) 2019-09-05 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
US10954310B2 (en) 2010-08-02 2021-03-23 Regeneran Pharmaceuticals, Inc. Mice that make VL binding proteins
WO2021058744A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
WO2021105391A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination comprising nupr1 inhibitors to treat cancer
WO2021105384A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US11136403B2 (en) 2017-10-13 2021-10-05 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US11180563B2 (en) 2020-02-21 2021-11-23 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
WO2021233962A1 (en) 2020-05-19 2021-11-25 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
WO2021255204A1 (en) 2020-06-18 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022084399A1 (en) 2020-10-21 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) C-terminal sparc fragments for treating cancer
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2022162192A2 (en) 2021-01-29 2022-08-04 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2022171777A1 (en) 2021-02-12 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for prognosis and treating a patient suffering from cancer
WO2022219076A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
WO2022253910A1 (en) 2021-06-02 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) A new method to treat an inflammatory skin disease
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2023012343A1 (en) 2021-08-06 2023-02-09 Institut Du Cancer De Montpellier Methods for the treatment of cancer
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023073099A1 (en) 2021-10-28 2023-05-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2023078906A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating acute myeloid leukemia
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023144392A1 (en) 2022-01-28 2023-08-03 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
WO2024028476A1 (en) 2022-08-05 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en) 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer
WO2024049951A1 (en) 2022-08-31 2024-03-07 Alexion Pharmaceuticals, Inc. Dosage and administration of fusion polypeptides for treatment of sickle cell disease
WO2024123963A2 (en) 2022-12-07 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
US12065486B2 (en) 2014-12-10 2024-08-20 Trustees Of Tufts College VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
WO2024184479A1 (en) 2023-03-08 2024-09-12 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of food allergy
WO2024184476A1 (en) 2023-03-07 2024-09-12 Institut Curie Ung/udg inhibition in brca-associated cancer
WO2024194401A1 (en) 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194692A1 (en) 2023-03-21 2024-09-26 Institut Curie Tgf-beta inhibitor for use in the treatment of dedifferentiated liposarcoma
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024213782A1 (en) 2023-04-13 2024-10-17 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024256527A1 (en) 2023-06-13 2024-12-19 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2025024645A1 (en) 2023-07-25 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rapid method for producing antibodies
WO2025032112A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of type 2-mediated diseases
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078851A1 (en) 2023-10-11 2025-04-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of treating cognitive deficit
WO2025162980A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of breast cancer using a jnk-1 inhibitor
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
US12415860B2 (en) 2018-05-14 2025-09-16 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
WO2025191018A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025231143A1 (en) 2024-04-30 2025-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against ev-d68
US12486335B2 (en) 2021-12-14 2025-12-02 Regeneron Pharmaceuticals, Inc. Mice that make VL binding proteins

Families Citing this family (1104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2258518C (en) * 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
WO1998015581A1 (en) * 1996-10-10 1998-04-16 Cytel Corporation Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
EP1051493A2 (en) * 1998-01-26 2000-11-15 Unilever Plc Method for producing antibody fragments
DE69920897T2 (de) * 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoklonale antikörper mit verringerter immunisierungsfähigkeit
BR0009866A (pt) * 1999-04-22 2002-01-08 Unilever Nv Método de inibição de infecção viral, uso de uma proteìna de ligação de antìgeno monovalente, produto alimentìcio, composição farmacêutica ou cosmética, proteìna de ligação de antìgeno monovalente, sequência de nucleotìdeos, vetor de expressão, célula hospedeira, e, métodos de seleção e de indentificação de uma proteìna de ligação de antìgeno
BR0012711A (pt) 1999-07-27 2002-04-09 Unilever Nv Composição detergente enzimática, e, processos para aumentar a atividade e / ou a estabilidade de uma oxidorredutase dependente de co-fator e para branquear manchas presentes em tecidos
DE60019309T2 (de) * 1999-09-16 2005-09-22 Unilever Plc Abgabesystem für ein mittel gegen schuppen
EP1088892A1 (en) * 1999-09-24 2001-04-04 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DK1242460T3 (da) 1999-11-29 2006-12-11 Unilever Nv Immobilisering af proteiner ved hjælp af et polypeptidsegment
EP1118669A3 (en) * 1999-12-17 2001-08-29 Unilever Plc Production of camelid antibodies in plants
ATE428733T1 (de) 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
US6696620B2 (en) * 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7858559B2 (en) * 2000-11-17 2010-12-28 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20060064782A1 (en) * 2000-12-18 2006-03-23 Conopco, Inc. Production of antibodies
EP1368380B1 (en) 2000-12-19 2009-09-02 Unilever N.V. Stabilisation of heavy chain Camelid antibodies with potassium salts
ATE519783T1 (de) * 2000-12-22 2011-08-15 Grad Carole Legal Representative Of Kaplan Howard ßPHAGE DISPLAYß BIBLIOTHEKE VON MENSCHLICHEN VH FRAGMENTEN
US20050069538A1 (en) * 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456237A2 (en) * 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
EP1474444A1 (en) 2002-01-10 2004-11-10 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A novel splice variant of myd88 and uses thereof
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2894009C (en) 2002-07-15 2016-12-06 Board Of Regents, The University Of Texas System Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
EP1527346B1 (en) 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
ES2381617T5 (es) 2002-08-14 2016-02-24 Macrogenics, Inc. Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
GB0219720D0 (en) * 2002-08-23 2002-10-02 Univ Aberdeen Polypeptide
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2004062551A2 (en) 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
EP1437764A1 (en) * 2003-01-10 2004-07-14 S.O.I. Tec Silicon on Insulator Technologies S.A. A compliant substrate for a heteroepitaxy, a heteroepitaxial structure and a method for fabricating a compliant substrate
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
LT3095793T (lt) 2003-07-28 2020-07-10 Genentech, Inc. Baltymo a išplovimo sumažinimas afininės baltymo a chromatografijos metu
US20050221383A1 (en) 2003-08-08 2005-10-06 Choong-Chin Liew Osteoarthritis biomarkers and uses thereof
EP1687452A4 (en) * 2003-09-30 2008-08-06 Centocor Inc HUMAN HINGE-CORE MIMETICORPS, COMPOSITIONS, METHODS AND APPLICATIONS THEREOF
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
CA2547635C (en) * 2003-12-12 2016-02-09 Jeffrey Schlom A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1750759A4 (en) * 2004-06-04 2008-06-04 Genencor Int SCREENING PROCEDURE USING ANTIBODY HEAVY CHAINS
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
SG188080A1 (en) 2004-07-22 2013-03-28 Univ Erasmus Medical Ct Binding molecules
RU2401842C2 (ru) 2004-10-08 2010-10-20 Домантис Лимитед Антагонисты и способы их применения
KR20070084170A (ko) * 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1836500B1 (en) 2005-01-14 2010-07-07 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
CA2595682A1 (en) * 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006086242A2 (en) 2005-02-07 2006-08-17 Genenews, Inc. Mild osteoarthritis biomarkers and uses thereof
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
CA2599465A1 (en) 2005-03-11 2006-09-14 Syngenta Limited Antibody based rodenticide
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
JP4986997B2 (ja) 2005-05-20 2012-07-25 アブリンクス エン．ヴェー． 凝集媒介障害の治療における改良ナノボディ（商標）
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
CA2620802A1 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
NZ566424A (en) 2005-09-01 2011-10-28 Schering Corp Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EP1943341A4 (en) * 2005-09-27 2010-07-07 Ca Nat Research Council BLOOD-BRAIN-SPEED-EPITOPES AND USES THEREOF
AU2006297304B2 (en) * 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
JP5237817B2 (ja) 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド バイオマーカー産物レベルを疾患に相関させるための方法および装置
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
EP1976991A1 (en) * 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
AU2007247137A1 (en) 2006-05-02 2007-11-15 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
CA2655080A1 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
SG170032A1 (en) 2006-08-28 2011-04-29 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
WO2008044928A1 (en) 2006-10-10 2008-04-17 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
WO2008055924A1 (en) 2006-11-07 2008-05-15 Vib Vzw Diagnosis and treatment of t-cell acute lymphoblastic leukemia
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
CN101611056A (zh) * 2006-12-05 2009-12-23 埃博灵克斯股份有限公司 能够结合于血清蛋白的肽
KR20090088950A (ko) 2006-12-14 2009-08-20 쉐링 코포레이션 가공된 항-ｔｓｌｐ 항체
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
AU2008219216A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
KR101520110B1 (ko) 2007-02-23 2015-05-18 머크 샤프 앤드 돔 코포레이션 가공된 항-ＩＬ-23ｐ19 항체
WO2008103473A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
EP2056838B1 (en) 2007-02-28 2013-09-25 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
MX2009009283A (es) 2007-02-28 2009-11-18 Schering Corp Anticuerpos anti-interleuquina -23r de ingenieria.
PT2308514E (pt) 2007-03-23 2013-09-06 To Bbb Holding B V Conjugados para a administração orientada de medicamentos através da barreira hematoencefálica
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008136694A1 (en) 2007-05-04 2008-11-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
CA2685222C (en) 2007-05-14 2017-12-19 Medimmune, Llc Methods of reducing eosinophil levels
US10214588B2 (en) 2007-07-03 2019-02-26 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
AU2008276787B2 (en) 2007-07-13 2013-06-06 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian IgG
EP2188371B1 (en) 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
ES2663077T3 (es) 2007-11-02 2018-04-11 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
JP5514399B2 (ja) * 2007-11-02 2014-06-04 国立大学法人 岡山大学 無機硫黄化合物加水分解酵素の製造方法
WO2009068628A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Constructs comprising single variable domains and an fc portion derived from lge.
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
AU2009212747B2 (en) 2008-01-31 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
EP2281005B1 (en) 2008-04-03 2013-11-20 Vib Vzw Single domain antibodies capable of modulating bace1 activity
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
PL2274331T3 (pl) 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CA2731617A1 (en) 2008-07-22 2010-01-28 Maria Joao Saraiva Amino acid sequences directed against multitarget scavenger receptors and polypeptides
HRP20150799T1 (hr) 2008-08-05 2015-09-11 Novartis Ag Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2012504939A (ja) 2008-09-23 2012-03-01 ワイス・エルエルシー 架橋結合タンパク質による活性化シグナルの産生を予測するための方法
AU2009314311B2 (en) 2008-10-29 2013-01-10 Ablynx N.V. Methods for purification of single domain antigen binding molecules
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
CA2745218A1 (en) 2008-12-19 2010-06-24 Schering Corporation Feed supplement for mammalian cell culture and methods of use
EP2370465B1 (en) 2008-12-19 2019-01-23 Ablynx N.V. Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
ES2701649T3 (es) 2009-01-14 2019-02-25 Ablynx Nv Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
EP2394159B1 (en) 2009-02-04 2018-09-26 Molecular Innovations Assays for detecting prorenin, and antibodies used therein
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP6159528B2 (ja) 2009-03-24 2017-07-05 ワイス・エルエルシー 高濃縮のタンパク質治療薬を生成するための膜蒸発
CA2758191C (en) 2009-04-10 2015-06-30 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010230311B9 (en) 2009-04-27 2012-09-20 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit
SI2424895T1 (en) 2009-04-27 2018-01-31 Novartis Ag Ingredients and procedures for increasing muscle growth
US9464138B2 (en) 2009-04-30 2016-10-11 Ablynx N.V. Method for the production of domain antibodies
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
EP3205670A1 (en) 2009-06-05 2017-08-16 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
WO2011012646A2 (en) 2009-07-28 2011-02-03 F. Hoffmann-La Roche Ag Non-invasive in vivo optical imaging method
EP2459594A1 (en) 2009-07-31 2012-06-06 N.V. Organon Fully human antibodies to btla
US9133500B2 (en) 2009-08-10 2015-09-15 MorphoSys A6 Screening strategies for the identification of binders
PL2473528T3 (pl) 2009-09-03 2015-05-29 Ablynx Nv Stabilne formulacje polipeptydów i ich zastosowanie
EP3023438B1 (en) 2009-09-03 2020-03-11 Merck Sharp & Dohme Corp. Anti-gitr antibodies
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
EP2486056A1 (en) 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
DK2491056T3 (da) 2009-10-22 2021-10-25 Univ Twente Vhh til anvendelse i vævsreparation, organregenerering, organudskiftning og vævskonstruktion
WO2011050242A1 (en) 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
AU2010336029B2 (en) 2009-12-23 2011-10-13 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
JP2013518853A (ja) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
PL2533761T3 (pl) 2010-02-11 2019-09-30 Ablynx N.V. Sposoby i kompozycje do wytwarzania aerozoli
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
EA201201227A1 (ru) 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные а-бета-связывающие полипептиды
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US20130041349A1 (en) 2010-03-26 2013-02-14 Westfaelische Wilhelms-Universitaet Muenster Substitute therapy for glucocorticoids
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
EP2555614B1 (en) 2010-04-06 2018-11-14 Agrosavfe N.V. Specific delivery of agrochemicals
PT2563813E (pt) 2010-04-30 2015-11-26 Alexion Pharma Inc Anticorpos anti-c5a e métodos para utilização dos anticorpos
ES2596431T3 (es) 2010-05-04 2017-01-09 The Brigham And Women's Hospital, Inc. Antagonista de cadherina-11 para el tratamiento de fibrosis
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
BR112012028006A2 (pt) 2010-05-07 2016-08-02 Hoffmann La Roche método de imuno-histoquímica (ihq), uso de um domínio de ligação, kit e domínio de ligação terapeuticamente ativo
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
EA201291328A1 (ru) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
CA2805548A1 (en) 2010-07-02 2012-01-05 Vib Vzw The role of fragile x mental retardation gene and protein in cancer metastasis
EP2593476A2 (en) 2010-07-16 2013-05-22 Ablynx N.V. Modified single domain antigen binding molecules and uses thereof
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
GB201012845D0 (en) 2010-07-30 2010-09-15 Vib Vzw Inhibition of dicer function for treatment of cancer
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
EP2609116A1 (en) 2010-08-26 2013-07-03 Agrosavfe N.V. Insect binding antibodies
EP2609115B1 (en) 2010-08-26 2017-05-31 Agrosavfe N.V. Compositions for seed treatment
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
DK3279214T3 (da) 2010-10-29 2024-12-09 Ablynx Nv Fremgangsmåde til fremstilling af variable immunglobulin-enkeltdomæner
GB201018602D0 (en) 2010-11-04 2010-12-22 Vib Vzw MMP8 inactivating antigen binding proteins
KR101931936B1 (ko) 2010-11-05 2018-12-26 에이자이 아이엔씨. 엽산 수용체 알파-발현 암에 대한 진단 및 예후 마커로서의 엽산 수용체 알파
NZ610075A (en) 2010-11-08 2015-03-27 Novartis Ag Cxcr2 binding polypeptides
WO2012084895A2 (en) 2010-12-20 2012-06-28 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US9850315B2 (en) 2011-02-01 2017-12-26 Bac Ip B.V. Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies
AR085141A1 (es) 2011-02-03 2013-09-11 Alexion Pharma Inc Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
EP2683413A1 (en) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
EP2686016B1 (en) 2011-03-14 2019-05-01 Cellmid Limited Antibody recognizing n-domain of midkine
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
ES2688591T3 (es) 2011-03-28 2018-11-05 Ablynx N.V. Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
JP6130350B2 (ja) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
CA2827787A1 (en) 2011-03-30 2012-10-04 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
RS57492B1 (sr) 2011-03-31 2018-10-31 Merck Sharp & Dohme Stabilne formulacije antitela za humani receptor programirane smrti pd-1 i srodni tretmani
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2707382B1 (en) 2011-05-09 2019-07-17 Ablynx NV Method for the production of immunoglobulin single variable domains
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
KR102072250B1 (ko) 2011-05-27 2020-03-02 아블린쓰 엔.브이. Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제
AU2012269720B2 (en) 2011-06-13 2015-01-22 Csl Limited Antibodies against G-CSFR and uses thereof
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
CA2839834A1 (en) 2011-06-21 2012-12-27 Vib Vzw Binding domains directed against gpcr:g protein complexes and uses derived thereof
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
LT2723771T (lt) 2011-06-23 2019-12-10 Ablynx Nv Serumo albuminą surišantys baltymai
DK2726099T3 (da) 2011-07-01 2018-11-05 Novartis Ag Fremgangsmåde til behandling af metaboliske lidelser
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
UY34254A (es) 2011-08-17 2013-04-05 Glaxo Group Ltd Proteínas y péptidos modificados.
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CN103889451B (zh) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2013054307A2 (en) 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
US9127056B2 (en) 2011-10-17 2015-09-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
US9265817B2 (en) 2011-10-28 2016-02-23 Patrys Limited PAT-LM1 epitopes and methods for using same
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
ES2649098T3 (es) 2011-11-11 2018-01-10 Ucb Biopharma Sprl Anticuerpos de unión a albumina y fragmentos de unión de los mismos
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
EA201491107A1 (ru) 2011-12-05 2014-11-28 Новартис Аг Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
WO2013084147A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
SG11201403416TA (en) 2011-12-21 2014-07-30 Novartis Ag Compositions and methods for antibodies targeting factor p
LT2804878T (lt) 2012-01-20 2018-12-10 Genzyme Corporation Anti-cxcr3 antikūnai
WO2013113696A1 (en) 2012-01-30 2013-08-08 Vib Vzw Means and method for diagnosis and treatment of alzheimer's disease
WO2013121042A1 (en) 2012-02-16 2013-08-22 Vib Vzw PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
MX349192B (es) 2012-02-27 2017-07-18 Boehringer Ingelheim Int Polipeptidos de union a cx3cr1.
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
SI2831111T1 (sl) 2012-03-30 2019-06-28 Boehringer Ingelheim International Gmbh Ang2-vezavne molekule
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
AU2013265665B2 (en) 2012-05-24 2017-10-26 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP3750560A3 (en) 2012-10-09 2021-03-24 Biogen MA Inc. Combination therapies and uses for treatment of demyelinating disorders
US9663797B2 (en) 2012-11-20 2017-05-30 Novartis Ag Optimized expression cassette for expressing a polypeptide with high yield
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
AP2015008365A0 (en) 2012-12-05 2015-04-30 Novartis Ag Compositions and methods for antibodies targeting epo
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
WO2014099997A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
SG11201504764SA (en) 2012-12-19 2015-07-30 Amplimmune Inc Anti-human b7-h4 antibodies and their uses
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP2935332B1 (en) 2012-12-21 2021-11-10 MedImmune, LLC Anti-h7cr antibodies
EP2951201B1 (en) 2013-01-30 2017-10-18 VIB vzw Novel chimeric polypeptides for screening and drug discovery purposes
CA2900147C (en) 2013-02-05 2023-09-05 Vib Vzw Muscarinic acetylcholine receptor binding agents and uses thereof
CN110551217B (zh) 2013-02-07 2023-12-15 Csl有限公司 Il-11r结合蛋白及其应用
ES2758473T3 (es) 2013-02-08 2020-05-05 Novartis Ag Anticuerpos anti-IL-17A y su uso en el tratamiento de trastornos autoinmunitarios e inflamatorios
MX2015010350A (es) 2013-02-26 2015-10-29 Roche Glycart Ag Moleculas de union a antigeno biespecificas que activan la celula t.
JP6416793B2 (ja) 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド 結核のバイオマーカー及びその使用
EA035943B1 (ru) 2013-03-13 2020-09-03 Протена Биосайенсес Лимитед Антитело, связывающееся с тау-белком человека
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
EP3623380B1 (en) 2013-03-15 2025-10-22 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
AU2014229952B2 (en) 2013-03-15 2018-10-04 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
WO2014146575A1 (en) 2013-03-19 2014-09-25 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
CN105358698B (zh) 2013-04-29 2024-02-20 生物催化公司 包含结合至鞘脂的抗体的农用化学组合物
EP2994163B1 (en) 2013-05-09 2019-08-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10316092B2 (en) 2013-05-24 2019-06-11 The John Hopkins University Anti-B7-H5 antibodies and their uses
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
WO2014207173A1 (en) 2013-06-27 2014-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
WO2015001082A1 (en) 2013-07-05 2015-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
JP6211701B2 (ja) 2013-08-07 2017-10-11 アレクシオン ファーマシューティカルズ， インコーポレイテッド 非典型溶血性尿毒症症候群のバイオマーカータンパク質
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
EP3530286A1 (en) 2013-11-28 2019-08-28 CSL Limited Method of treating diabetic nephropathy
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
ES2851386T3 (es) 2013-12-18 2021-09-06 Csl Ltd Método de tratamiento de las heridas
EP3083964B1 (en) 2013-12-19 2022-01-26 Novartis AG Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
BR112016014284A2 (pt) 2013-12-20 2017-12-05 Intervet Int Bv anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JP6687525B2 (ja) 2014-01-30 2020-04-22 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ オピオイド受容体結合剤およびその使用
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子およびその使用
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
KR20220126813A (ko) 2014-03-14 2022-09-16 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
MX370018B (es) 2014-04-25 2019-11-28 Bluebird Bio Inc Metodos mejorados para la elaboracion de terapias celulares adoptivas.
LT3134432T (lt) 2014-04-25 2020-04-10 Bluebird Bio, Inc. Mnd promotorius chimerinių antigenų receptoriams
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP3702369A1 (en) 2014-05-16 2020-09-02 Ablynx NV Immunoglobulin variable domains
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
LT3151672T (lt) 2014-06-06 2021-02-10 Bluebird Bio, Inc. Patobulintos t ląstelių kompozicijos
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
PT3194976T (pt) 2014-07-22 2020-07-03 Univ Brussel Vrije Métodos para selecionar agentes que estabilizam complexos proteicos
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
CA2954359C (en) 2014-07-29 2018-09-25 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TWI675043B (zh) 2014-08-07 2019-10-21 瑞士商諾華公司 血管生成素樣４抗體及其使用方法
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
MX389684B (es) 2014-08-19 2025-03-20 Merck Sharp & Dohme Llc Anticuerpos anti tigit.
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
MX2017003645A (es) 2014-09-17 2017-05-30 Novartis Ag Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP2017538779A (ja) 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Ｒｓｖ感染の治療方法
CN106999420B (zh) 2014-10-10 2021-08-10 埃博灵克斯股份有限公司 用于呼吸系统疾病的气溶胶疗法的吸入装置
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
US10584175B2 (en) 2014-10-23 2020-03-10 La Trobe University FN14-binding proteins and uses thereof
AR102550A1 (es) 2014-11-05 2017-03-08 Agrosavfe Nv Planta transgénica que comprende un polinucleótido que codifica un dominio variable de anticuerpo de cadena pesada
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
RS61249B1 (sr) 2014-12-11 2021-01-29 Pf Medicament Antitela na c10orf54 i njihova upotreba
CN112358551B (zh) 2014-12-12 2024-02-02 2赛文缇生物公司 Bcma嵌合抗原受体
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
ES2772348T3 (es) 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína
ES2862701T3 (es) 2014-12-22 2021-10-07 Univ Rockefeller Anticuerpos agonistas anti-MERTK y usos de los mismos
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
MX391051B (es) 2014-12-30 2025-03-21 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
JP6885867B2 (ja) 2014-12-31 2021-06-16 チェックメイト ファーマシューティカルズ， インコーポレイテッド 組合せ腫瘍免疫療法
HK1246810A1 (zh) 2015-01-08 2018-09-14 Biogen Ma Inc. Lingo-1对抗药及用於治疗脱髓鞘疾病的用途
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016124568A1 (en) 2015-02-03 2016-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-rho gtpase conformational single domain antibodies and uses thereof
WO2016128549A1 (en) 2015-02-13 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
CN108064169B (zh) 2015-03-03 2022-02-11 科马布有限公司 抗体、用途和方法
ES2929614T3 (es) 2015-03-17 2022-11-30 Memorial Sloan Kettering Cancer Center Anticuerpos anti-MUC16 y usos de los mismos
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
TR201904903T4 (tr) 2015-03-25 2019-05-21 Alexion Pharma Inc Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem.
EP3274724A1 (en) 2015-03-25 2018-01-31 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
JP6895421B2 (ja) 2015-03-31 2021-06-30 ブイエイチスクエアード リミテッド ポリペプチド
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
ES3029413T3 (en) 2015-04-02 2025-06-24 Ablynx Nv Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
CN107683291B (zh) 2015-04-02 2021-11-19 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
CN108473957B (zh) 2015-04-17 2024-07-16 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
BR112017023849A2 (pt) 2015-05-07 2018-07-17 Agenus Inc. anticorpos anti-ox40 e métodos de uso dos mesmos
WO2016183183A1 (en) 2015-05-11 2016-11-17 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
EP3294768B1 (en) 2015-05-13 2019-08-21 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
DK3294319T3 (da) 2015-05-13 2024-07-22 Ablynx Nv T-celle-rekrutterende polypeptider baseret på cd3-reaktivitet
EP3302553A4 (en) 2015-05-28 2019-03-06 Bio-rad Laboratories, Inc. AFFINITY LIGANDS AND APPROPRIATE PROCEDURES
PE20180672A1 (es) 2015-05-29 2018-04-19 Agenus Inc Anticuerpos anti-ctla-4 y metodos de uso de los mismos
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2016207313A1 (en) 2015-06-24 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for detecting protein-protein interactions
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
AU2016294858B2 (en) 2015-07-17 2022-08-11 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer
WO2017015427A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
WO2017023760A1 (en) 2015-07-31 2017-02-09 Prudent James R Extracellular drug conjugates targeting cd20
CA2994516A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
AU2016306907A1 (en) 2015-08-07 2018-03-29 Merck Patent Gmbh A transglutamine tag for efficient site-specific bioconjugation
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
ES2992478T3 (es) 2015-08-11 2024-12-12 Wuxi Biologics Ireland Ltd Nuevos anticuerpos anti-PD-1
ES2911015T3 (es) 2015-08-31 2022-05-17 Helixmith Co Ltd Receptores quiméricos de antígeno anti-sialil Tn
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
MA55472A (fr) 2015-09-09 2022-02-09 Novartis Ag Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
CN108699555A (zh) 2015-10-09 2018-10-23 萨勒普塔医疗公司 用于治疗杜兴肌营养不良和相关病症的组合物和方法
CN105238759B (zh) * 2015-10-14 2019-05-24 吉日木图 抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
KR20180101341A (ko) 2015-11-10 2018-09-12 비스테라, 인크. 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
NO2768984T3 (da) 2015-11-12 2018-06-09
WO2017081190A1 (en) 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
MA43259A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants ctla4
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
CA3003200A1 (en) 2015-11-27 2017-06-01 Csl Limited Cd131 binding proteins and uses thereof
MX380414B (es) 2015-12-04 2025-03-12 Boehringer Ingelheim Int Polipeptidos biparatopicos que antagonizan la señalizacion wnt en celulas tumorales.
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
EP3386542B1 (en) 2015-12-10 2020-11-18 Katholieke Universiteit Leuven Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
CA3007421A1 (en) 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017103895A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017117112A1 (en) 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
ES2981745T3 (es) 2016-02-05 2024-10-10 Orionis Biosciences BV Agentes de señalización biespecíficos y usos de los mismos
AU2017219254B2 (en) 2016-02-17 2019-12-12 Novartis Ag TGFbeta 2 antibodies
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
AU2017238172B2 (en) 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
JP7080213B2 (ja) 2016-03-23 2022-06-03 スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド 新規抗ｐｄ－ｌ１抗体
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW202302144A (zh) 2016-03-25 2023-01-16 美商威特拉公司 登革病毒的抗體分子之配方設計
ES2866880T3 (es) 2016-04-13 2021-10-20 Inst Nat Sante Rech Med Métodos y kits para la detección rápida del clon O25B-ST131 de Escherichia Coli
US11976116B2 (en) 2016-04-14 2024-05-07 2Seventy Bio, Inc. Salvage chimeric antigen receptor systems
US20170298119A1 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
SG11201809041TA (en) 2016-04-15 2018-11-29 Novartis Ag Compositions and methods for selective protein expression
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
WO2017182603A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
US20190127447A1 (en) 2016-05-02 2019-05-02 Ablynx N.V. Treatment of rsv infection
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
MA55697A (fr) 2016-05-18 2022-02-23 Boehringer Ingelheim Int Molécules d'anticorps pour le traitement du cancer
EP3463452A1 (en) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
US20170342139A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for Treatment of Refractory Generalized Myasthenia Gravis
EP3463482B1 (en) 2016-06-07 2021-10-06 The Brigham and Women's Hospital, Inc. Methods relating to t peripheral helper cells in autoantibody-associated conditions
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
WO2017223419A1 (en) 2016-06-24 2017-12-28 Ig Biosciences Corporation Prebiotic neutraceutical compositions and methods of treatment using the same
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
JP2019525772A (ja) 2016-07-08 2019-09-12 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
EP3484512A1 (en) 2016-07-13 2019-05-22 Biogen MA Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3487521A4 (en) 2016-07-21 2020-07-01 Emory University ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
KR20250061769A (ko) 2016-07-28 2025-05-08 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
JP2019527696A (ja) 2016-08-01 2019-10-03 ノバルティス アーゲー プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
CA3032826A1 (en) 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
JP2020502991A (ja) 2016-09-20 2020-01-30 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｐｃｓｋ９抗体
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
CN110035769A (zh) 2016-09-21 2019-07-19 奈斯科尔公司 针对siglec-15的抗体及其使用方法
AU2017331277B2 (en) 2016-09-23 2024-05-30 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
AU2017343621B2 (en) 2016-10-11 2021-12-02 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
WO2018071624A1 (en) 2016-10-12 2018-04-19 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
GB2573406B (en) 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
JP7173965B2 (ja) 2016-10-19 2022-11-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合Ｃ５ａの定量化方法
JP7096240B2 (ja) 2016-10-19 2022-07-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合ｃ５の定量化方法
CN110291102A (zh) 2016-10-21 2019-09-27 国立卫生和医学研究所 促进t细胞应答的方法
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
JP7100030B2 (ja) 2016-10-28 2022-07-12 アスチュート メディカル，インコーポレイテッド 腎機能の改善のためのｔｉｍｐ－２に対する抗体の使用
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20190082241A (ko) 2016-11-04 2019-07-09 블루버드 바이오, 인코포레이티드. 항-bcma car t 세포 조성물
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
CA3043515A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018094244A1 (en) 2016-11-17 2018-05-24 Bluebird Bio, Inc. TGFβ SIGNAL CONVERTOR
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
JP2020508436A (ja) 2016-12-07 2020-03-19 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
WO2018112240A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US11597762B2 (en) 2016-12-14 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
BR112019012071A2 (pt) 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
EP3554346B1 (en) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US11134889B2 (en) 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
EP4190318A1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
WO2018112256A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554344A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
IL267565B2 (en) 2016-12-23 2025-02-01 Visterra Inc Methods of producing binding polypeptides containing covalently linked heavy chains and light chains
EP3565560B1 (en) 2017-01-09 2024-05-29 OnkosXcel Therapeutics, LLC Predictive and diagnostic methods for prostate cancer
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN110573604A (zh) 2017-02-28 2019-12-13 非营利性组织佛兰芒综合大学生物技术研究所 用于口服蛋白质递送的工具和方法
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3596464B1 (en) 2017-03-14 2021-08-11 NanoTag Biotechnologies GmbH Target detection using a monovalent antibody
WO2018166495A1 (en) 2017-03-15 2018-09-20 Tsinghua University Novel anti-trkb antibodies
IL269083B2 (en) 2017-03-24 2024-12-01 Novartis Ag Methods for preventing and treating heart disease
US20200330590A1 (en) 2017-03-27 2020-10-22 Celgene Corporation Methods and compositions for reduction of immunogenicity
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
EP3600249A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
CA3054947A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3600414A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
EP3606960A1 (en) 2017-04-03 2020-02-12 Oncologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
US20200033347A1 (en) 2017-04-18 2020-01-30 Universite Libre De Bruxelles Biomarkers And Targets For Proliferative Diseases
US20200123238A1 (en) 2017-04-19 2020-04-23 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP4328241A3 (en) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
US11891451B2 (en) 2017-05-11 2024-02-06 Vib Vzw Glycosylation of variable immunoglobulin domains
AU2018266562A1 (en) 2017-05-12 2019-12-05 Augusta University Research Institute, Inc. Human alpha fetoprotein-specific T cell receptors and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
MX2019014331A (es) 2017-05-31 2020-01-27 Boehringer Ingelheim Int Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
KR20250036278A (ko) 2017-06-02 2025-03-13 메르크 파텐트 게엠베하 Mmp13 결합성 면역글로불린
MX2019014199A (es) 2017-06-02 2020-01-23 Boehringer Ingelheim Int Tratamiento de combinacion antineoplasico.
KR20250011229A (ko) 2017-06-02 2025-01-21 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
EP3415010A1 (en) 2017-06-13 2018-12-19 Agrosavfe Nv Insect-controlling polypeptides and methods
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2019015738A (es) 2017-06-27 2020-02-20 Novartis Ag Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
EP3645041A4 (en) 2017-06-28 2021-03-17 The Rockefeller University AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES
RU2019143078A (ru) 2017-06-28 2021-07-28 Новартис Аг Способы предупреждения и лечения недержания мочи
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
IL271920B2 (en) 2017-07-11 2024-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
SG10201913144TA (en) 2017-07-11 2020-03-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw AGENTS FOR CONNECTING TO SERUM ALBUMIN
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
US11365241B2 (en) 2017-07-27 2022-06-21 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
JP2020529605A (ja) 2017-08-01 2020-10-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 濾過およびクロマトグラフィ用ポッドならびにその使用方法
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
KR20200045520A (ko) 2017-09-07 2020-05-04 오거스타 유니버시티 리서치 인스티튜트, 인크. 프로그래밍된 세포사 단백질 1에 대한 항체
EP4512469A3 (en) 2017-09-11 2025-05-21 Monash University Binding proteins to the human thrombin receptor, par4
EP3684471A1 (en) 2017-09-20 2020-07-29 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for modulating autophagy
EP3692069A1 (en) 2017-10-02 2020-08-12 Visterra, Inc. Antibody molecules to cd138 and uses thereof
ES2759622T3 (es) 2017-10-02 2020-05-11 Certest Biotec S L Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
KR102715492B1 (ko) 2017-10-18 2024-10-11 씨에스엘 리미티드 인간 혈청 알부민 변이체 및 이의 용도
AU2018353432A1 (en) 2017-10-19 2020-04-23 Debiopharm International S.A. Combination product for the treatment of cancer
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
AU2018354404B2 (en) 2017-10-26 2025-10-30 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
JP7039694B2 (ja) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
JP7760115B2 (ja) 2017-10-31 2025-10-27 フエー・イー・ベー・フエー・ゼツト・ウエー 新規抗原結合性キメラタンパク質とその方法及び使用
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
DK3717011T5 (da) 2017-11-29 2024-08-26 Csl Ltd Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
JP2021505207A (ja) 2017-12-05 2021-02-18 セリアド エス．アー．Ｃｅｌｙａｄ Ｓ．Ａ． Ｎｋｇ２ｄベースの受容体を発現する免疫細胞のフラトリサイドの減少
US12173316B2 (en) 2017-12-05 2024-12-24 Celyad S.A Compositions and methods for improving persistence of cells for adoptive transfer
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN109970857B (zh) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129221A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
CN108218990B (zh) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019140116A2 (en) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
KR20250114571A (ko) 2018-01-15 2025-07-29 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
EP3740231A4 (en) 2018-01-18 2022-03-23 California Institute of Technology PROGRAMMABLE PROTEIN CIRCUITS IN LIVING CELLS
JP2021512151A (ja) 2018-01-23 2021-05-13 ネクストキュア インコーポレイテッド Ｂ７−ｈ４抗体およびその使用方法
JP2021510594A (ja) 2018-01-25 2021-04-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 臓器の虚血再灌流傷害を予防する方法における使用のためのｉｌ−３３のアンタゴニスト
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
CA3089988A1 (en) 2018-02-01 2019-08-08 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
JP2021513361A (ja) 2018-02-05 2021-05-27 オリオニス バイオサイエンシーズ，インコーポレイテッド 線維芽細胞結合物質およびその使用
EP3749696A1 (en) 2018-02-06 2020-12-16 Ablynx N.V. Methods of treating initial episode of ttp with immunoglobulin single variable domains
WO2019157191A1 (en) 2018-02-07 2019-08-15 Georgia Tech Research Corporation Methods for multiplexed cell isolation using dna gates
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US11858960B2 (en) 2018-03-01 2024-01-02 Vrije Universiteit Brussel Human PD-L1-binding immunoglobulins
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
MX2020009507A (es) 2018-03-13 2020-10-22 Smivet B V Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
EP4043496A1 (en) 2018-03-14 2022-08-17 Surface Oncology, Inc. Antibodies that bind cd39 and uses thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019179420A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
US11332524B2 (en) 2018-03-22 2022-05-17 Surface Oncology, Inc. Anti-IL-27 antibodies and uses thereof
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
AU2019237215B2 (en) 2018-03-23 2023-11-02 Université Libre de Bruxelles Wnt signaling agonist molecules
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
JP2021519093A (ja) 2018-03-27 2021-08-10 ユーエムシー ユトレヒト ホールディング ビー．ブイ． 微小血管血栓症の処置のための標的化血栓溶解
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
JP7511478B2 (ja) 2018-04-09 2024-07-05 チェックメイト ファーマシューティカルズ ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
WO2019217913A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
EP3790898A4 (en) 2018-05-10 2022-03-02 Neuracle Science Co., Ltd SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
EP3797120A1 (en) 2018-05-21 2021-03-31 Compass Therapeutics LLC Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP7520725B2 (ja) 2018-05-31 2024-07-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
SG11202010579XA (en) 2018-06-01 2020-12-30 Novartis Ag Binding molecules against bcma and uses thereof
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof
CA3110836A1 (en) 2018-06-14 2019-12-19 Bluebird Bio, Inc. Cd79a chimeric antigen receptors
CN113166266B (zh) 2018-06-18 2025-06-24 上海偌妥生物科技有限公司 抗间皮素构建体及其用途
CA3104295A1 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3814373A1 (en) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
CN118754985A (zh) 2018-06-29 2024-10-11 爱必泰生物有限公司 抗l1cam抗体及其用途
CN112351998B (zh) 2018-06-29 2022-07-22 苏州智核生物医药科技有限公司 Pd-l1结合多肽及其用途
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
WO2020014333A1 (en) 2018-07-11 2020-01-16 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
ES2738926A1 (es) 2018-07-26 2020-01-27 Univ Zaragoza Granulisina, metodo de obtencion y usos
WO2020028909A1 (en) 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
US12460004B2 (en) 2018-08-09 2025-11-04 Compass Therapeutics Llc Antibodies that bind CD277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
WO2020047320A1 (en) 2018-08-31 2020-03-05 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
AU2019331496A1 (en) 2018-08-31 2021-03-18 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN112585169A (zh) 2018-09-04 2021-03-30 南京优迈生物科技有限公司 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2020048525A1 (en) 2018-09-07 2020-03-12 Generon (Shanghai) Corporation Ltd. Bispecific antigen binding proteins and uses thereof
US12365705B2 (en) 2018-09-11 2025-07-22 Nanotag Biotechnologies Gmbh Epitope tags recognized by specific binders
US12473357B2 (en) 2018-09-25 2025-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of Th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
BR112021004383A2 (pt) 2018-09-28 2021-08-03 Massachusetts Institute Of Technology proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
JP2022504287A (ja) 2018-10-03 2022-01-13 スターテン・バイオテクノロジー・ベー・フェー ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020092549A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
WO2020097350A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
AU2019379576A1 (en) 2018-11-13 2021-06-03 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
US12422441B2 (en) 2018-12-07 2025-09-23 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020120644A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
CA3121420A1 (en) 2018-12-13 2020-06-18 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
WO2020128894A1 (en) 2018-12-20 2020-06-25 Novartis Ag Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
AU2019409805A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
WO2020127369A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
KR20220008253A (ko) 2019-01-03 2022-01-20 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물
BR112021013337A2 (pt) 2019-01-07 2021-11-09 Bactolife Aps Proteínas de ligação a patógenos
EP3908653A4 (en) 2019-01-10 2022-11-02 California Institute of Technology A synthetic system for tunable thresholding of protein signals
JP7645185B2 (ja) 2019-01-15 2025-03-13 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
KR20210131312A (ko) 2019-01-16 2021-11-02 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 항체의 제제 및 이의 용도
TWI756621B (zh) 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
CA3129834A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
WO2020169707A1 (en) 2019-02-21 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Foxo1 inhibitor for use in the treatment of latent virus infection
CN114127112A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
WO2020185069A1 (en) 2019-03-08 2020-09-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
SG11202109172TA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Human carbonic anhydrase 2 compositions and methods for tunable regulation
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
KR20220029546A (ko) 2019-03-29 2022-03-08 아타르가, 엘엘씨 항 fgf23 항체
US12291562B2 (en) 2019-04-01 2025-05-06 Rush University Medical Center Reagents and assays using modified integrin domains
JP2022527825A (ja) 2019-04-03 2022-06-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体
US12331133B2 (en) 2019-04-04 2025-06-17 Vanderbilt University Therapeutic antibodies for treating lung cancer
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CN114041056A (zh) 2019-04-29 2022-02-11 康福治疗有限公司 用于跨膜蛋白尤其是gpcr的筛选方法和测定
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
KR20220007586A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 개선된 경쟁적 리간드 결합 검정
EP3969479B1 (en) 2019-05-14 2025-07-30 Harpoon Therapeutics, Inc. Epcam binding proteins and methods of use
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
EP3978532A4 (en) 2019-05-24 2023-10-18 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
EP3976650A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
CN113474372B (zh) 2019-06-04 2023-08-08 上海吉倍生物技术有限公司 一种抗ceacam5的单克隆抗体及其制备方法和用途
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
EP3983442A2 (en) 2019-06-17 2022-04-20 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
WO2020254619A1 (en) 2019-06-20 2020-12-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- protease nexin-1 conformational single domain antibodies and uses thereof
US20220242945A1 (en) 2019-06-21 2022-08-04 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2020295767A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Compositions
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021000886A1 (zh) 2019-07-01 2021-01-07 苏州康宁杰瑞生物科技有限公司 百日咳毒素结合蛋白
BR112022000721A2 (pt) 2019-07-15 2022-03-08 Intervet Int Bv Anticorpos caninizados contra ctla-4 canina
TWI889694B (zh) 2019-07-26 2025-07-11 美商威特拉公司 介白素-2藥劑及其用途
US20220324947A1 (en) 2019-08-05 2022-10-13 Stichting Vu Identification and Elimination of HCMV-Infected Cells
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
EP4031178A1 (en) 2019-09-16 2022-07-27 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US20210115127A1 (en) 2019-09-25 2021-04-22 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
TW202126295A (zh) 2019-09-27 2021-07-16 大陸商江蘇挪貝肽醫藥科技有限公司 一種治療心境障礙的方法
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
EP4048703A1 (en) 2019-10-21 2022-08-31 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
KR20220103947A (ko) 2019-10-21 2022-07-25 노파르티스 아게 베네토클락스 및 tim-3 억제제를 사용한 조합 요법
CA3157665A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
WO2021080682A1 (en) 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Monoclonal antibodies that bind human cd161 and uses thereof
US20230002785A1 (en) 2019-10-28 2023-01-05 Georgia Tech Research Corporation Mrna-encoded antibodies for contraception
US20240148901A1 (en) 2019-10-28 2024-05-09 Georgia Tech Research Corporation Compositions and methods for prophylaxis of hiv
CN115697387A (zh) 2019-11-05 2023-02-03 细胞基因公司 抗bcma嵌合抗原受体的用途
JP2023501004A (ja) 2019-11-11 2023-01-17 アイビーアイ－エージー イノベイティブ バイオ インセクティサイズ リミテッド 昆虫防除ナノボディおよびその使用
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
CA3158963A1 (en) 2019-11-22 2021-05-27 Samir Mitragotri Ionic liquids for drug delivery
MX2022006391A (es) 2019-11-26 2022-06-24 Novartis Ag Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
CN115151309A (zh) 2019-12-05 2022-10-04 Ose免疫疗法 抗clec-1a抗体及其抗原结合片段
MX2022006881A (es) 2019-12-06 2022-07-11 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
JP7657797B2 (ja) 2019-12-06 2025-04-07 アブリンクス エン．ヴェー． ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
EP4072674A1 (en) 2019-12-09 2022-10-19 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4076525A4 (en) 2019-12-20 2024-05-01 Momenta Pharmaceuticals, Inc. ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1
AU2020404453B2 (en) 2019-12-20 2022-12-08 Hudson Institute of Medical Research CXCL10 binding proteins and uses thereof
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
IL321341A (en) 2020-01-06 2025-08-01 Vaccinex Inc Anti-CCR8 antibodies and their uses
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2021207348A1 (en) 2020-01-17 2022-08-11 Novartis Ag Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CA3162913A1 (en) 2020-01-17 2021-07-22 Universiteit Gent Immunoglobulin single domain antibodies for delivery of mucosal vaccines
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
US20230111593A1 (en) 2020-02-14 2023-04-13 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
US20230087785A1 (en) 2020-02-25 2023-03-23 Vib Vzw Leucine-Rich Repeat Kinase 2 Allosteric Modulators
EP4110377A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
WO2021183675A2 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
CN115485295A (zh) 2020-03-10 2022-12-16 麻省理工学院 NPM1c阳性癌症的免疫疗法的组合物和方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
BR112022018088A2 (pt) 2020-03-12 2023-01-17 Immune Onc Therapeutics Inc Novos anticorpos anti-lilrb4 e produtos derivados
WO2021180205A1 (zh) 2020-03-13 2021-09-16 江苏恒瑞医药股份有限公司 Pvrig结合蛋白及其医药用途
EP4121756A1 (en) 2020-03-20 2023-01-25 GlaxoSmithKline Intellectual Property Development Limited Method for detecting polysorbates
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
MX2022012278A (es) 2020-03-30 2022-10-27 Ablynx Nv Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
AU2021250446A1 (en) 2020-03-31 2022-11-17 Biotalys NV Anti-fungal polypeptides
AU2021248643A1 (en) 2020-04-03 2022-10-27 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
AU2021257848A1 (en) 2020-04-15 2022-12-01 Voyager Therapeutics, Inc. Tau binding compounds
JP2023522208A (ja) 2020-04-16 2023-05-29 アシスタンス ピュブリック－オピト ド パリ ウイルスによって引き起こされる補体媒介性障害を処置する方法
CN113527488A (zh) 2020-04-22 2021-10-22 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
CA3180321A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US20230176070A1 (en) 2020-05-01 2023-06-08 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for identifying nanobodies and nanobody affinities
IL297412A (en) 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
CN115551553A (zh) 2020-05-12 2022-12-30 Inserm(法国国家健康医学研究院) 治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
CA3180665A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
EP3916088A1 (en) 2020-05-28 2021-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins comprising the sars-cov-2 3clpro catalytic domain and their uses for screening anti-sars-cov-2 agents
WO2021242794A2 (en) 2020-05-29 2021-12-02 President And Fellows Of Harvard College Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
CN111647077B (zh) 2020-06-02 2021-02-09 深圳市因诺赛生物科技有限公司 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
TW202214844A (zh) 2020-06-17 2022-04-16 美商健生生物科技公司 用於製造多能幹細胞之材料及方法
AU2021297315A1 (en) 2020-06-24 2023-02-02 Visterra, Inc. Antibody molecules to APRIL and uses thereof
AU2021299932A1 (en) 2020-06-29 2023-02-02 Assistance Publique-Hôpitaux De Paris (Aphp) Anti-protein S single-domain antibodies and polypeptides comprising thereof
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
CN115803348A (zh) 2020-07-03 2023-03-14 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
MX2023000547A (es) 2020-07-16 2023-02-13 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
EP4186925A4 (en) 2020-07-21 2025-01-22 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. CD8-BINDING POLYPEPTIDE AND USE THEREOF
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
IL300173A (en) 2020-07-31 2023-03-01 Biotalys NV Expression host
WO2022036159A2 (en) 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CN116917316A (zh) 2020-08-26 2023-10-20 马伦戈治疗公司 与NKp30结合的抗体分子及其用途
EP4204450A4 (en) 2020-08-26 2024-11-13 Marengo Therapeutics, Inc. MULTIFUNCTIONAL CALRETICULIN-BINDING MOLECULES AND RELATED USES
EP4204458A4 (en) 2020-08-26 2024-10-09 Marengo Therapeutics, Inc. METHODS FOR DETECTION OF TRBC1 OR TRBC2
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
KR20230069961A (ko) 2020-09-14 2023-05-19 보르 바이오파마 인크. Cd33에 대한 단일 도메인 항체
EP4214235A1 (en) 2020-09-16 2023-07-26 LinXis B.V. Internalizing binding molecules
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022063984A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022081804A1 (en) 2020-10-14 2022-04-21 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2022084355A2 (en) 2020-10-21 2022-04-28 Boehringer Ingelheim International Gmbh Agonistic trkb binding molecules for the treatment of eye diseases
WO2022098685A2 (en) 2020-11-04 2022-05-12 Celgene Corporation Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
CA3199839A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20240016936A1 (en) 2020-12-04 2024-01-18 Celgene Corporation Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
MX2023006599A (es) 2020-12-04 2023-06-19 Visterra Inc Metodos de uso de agentes de interleucina-2.
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
US20240052042A1 (en) 2020-12-14 2024-02-15 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
KR20230129441A (ko) 2020-12-17 2023-09-08 오제 이뮈노테라프틱스 이기능성 항-pd1/il-7 분자
KR20230123495A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
JP2023553694A (ja) 2020-12-18 2023-12-25 アブリンクス エン．ヴェー． ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
WO2022129637A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
WO2022136650A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Murine cross-reactive human ccr8 binders
EP4267618A1 (en) 2020-12-24 2023-11-01 Vib Vzw Non-blocking human ccr8 binders
MX2023008598A (es) 2021-01-20 2023-08-10 Visterra Inc Agentes de interleuquina-2 y usos de los mismos.
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
AU2022214006A1 (en) 2021-02-01 2023-09-21 St Phi Therapeutics Co., Ltd. Targeted protein degradation system and use thereof
AU2022217812A1 (en) 2021-02-05 2023-08-03 Salubris Biotherapeutics, Inc. Il-15 fusion proteins and methods of making and using same
US20240101647A1 (en) 2021-02-05 2024-03-28 Vib Vzw Sarbecovirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
KR102836732B1 (ko) 2021-02-19 2025-07-21 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
AU2022222994B2 (en) 2021-02-19 2025-11-27 Shaperon Inc. Single domain antibody against cd47 and use thereof
MX2023009715A (es) 2021-02-19 2024-01-08 Shaperon Inc Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo.
EP4294516A1 (en) 2021-02-19 2023-12-27 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
GB202104104D0 (en) 2021-03-24 2021-05-05 Liliumx Ltd Platform and method
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CN117441010A (zh) 2021-04-07 2024-01-23 世纪治疗股份有限公司 从诱导多能干细胞产生α-βT细胞的组合物和方法
IL307358A (en) 2021-04-07 2023-11-01 Century Therapeutics Inc Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022253223A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
US20240369570A1 (en) 2021-04-09 2024-11-07 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
IL307598A (en) 2021-04-16 2023-12-01 Juno Therapeutics Inc T-cell therapy in patients who have had a previous stem cell transplant
AU2022270075A1 (en) 2021-05-04 2023-11-09 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
CA3215856A1 (en) 2021-05-07 2022-11-10 Alison O'neill Anti-il-27 antibodies and uses thereof
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
US12252550B2 (en) 2021-05-20 2025-03-18 Dianthus Therapeutics Opco, Inc. Antibodies that bind to C1S and uses thereof
JP2024523436A (ja) 2021-06-16 2024-06-28 上海▲シン▼湾生物科技有限公司 Ａｘｌタンパク質を標的とする抗体及びその抗原結合断片、その調製方法と使用
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
AU2022299282A1 (en) 2021-06-22 2024-02-01 Merck Patent Gmbh Vhh-based nkp30 binders
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
CN114230665B (zh) 2021-06-23 2024-03-22 苏州智核生物医药科技有限公司 CD8α结合多肽及其用途
US20240287501A1 (en) 2021-06-23 2024-08-29 Vib Vzw Means and Methods for Selection of Specific Binders
JP2024524378A (ja) 2021-06-29 2024-07-05 山▲東▼先声生物制▲薬▼有限公司 Ｃｄ１６抗体及びその応用
WO2023288046A1 (en) 2021-07-15 2023-01-19 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
WO2023006040A1 (zh) 2021-07-30 2023-02-02 江苏先声药业有限公司 抗pvrig/抗tigit双特异性抗体和应用
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
MX2024002261A (es) 2021-08-24 2024-03-06 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union de fap/cd40 y uso medicinal de la misma.
CN117940453A (zh) 2021-09-15 2024-04-26 江苏恒瑞医药股份有限公司 特异性结合pd-1的蛋白及其医药用途
WO2023041985A2 (en) 2021-09-15 2023-03-23 New York University In Abu Dhabicorporation Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
CA3231553A1 (en) 2021-09-15 2023-03-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
US20250223376A1 (en) 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
AU2022359915A1 (en) 2021-10-08 2024-05-02 President And Fellows Of Harvard College Ionic liquids for drug delivery
KR20240082411A (ko) 2021-10-14 2024-06-10 라띠콘 (수저우) 바이오파마슈티칼스 코., 엘티디. 신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도
EP4177266A1 (en) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
WO2023079137A1 (en) 2021-11-05 2023-05-11 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
CN118510534A (zh) 2021-11-09 2024-08-16 Ose免疫疗法 Clec-1配体的识别及其用途
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
EP4180518A1 (en) 2021-11-12 2023-05-17 Istituto Europeo di Oncologia S.r.l. T cells and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN118302818A (zh) 2021-11-22 2024-07-05 阿布林克斯有限公司 获得目标多价免疫球蛋白单可变结构域的序列信息
EP4436982A1 (en) 2021-11-24 2024-10-02 Novartis AG Modulators of adeno-associated virus transduction and uses thereof
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
CN118339179A (zh) 2021-11-29 2024-07-12 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
CN116199782A (zh) 2021-11-30 2023-06-02 苏州康宁杰瑞生物科技有限公司 预防和/或治疗血栓栓塞性疾病的方法
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
JP2024541668A (ja) 2021-12-03 2024-11-08 山▲東▼先声生物制▲薬▼有限公司 抗ｂｃｍａナノ抗体及びその応用
WO2023114884A2 (en) 2021-12-15 2023-06-22 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
CN118510805A (zh) 2021-12-31 2024-08-16 山东先声生物制药有限公司 一种gprc5d抗体及其应用
EP4209508A1 (en) 2022-01-11 2023-07-12 Centre national de la recherche scientifique Nanobodies for the deneddylating enzyme nedp1
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
KR20240137086A (ko) 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
US20250129387A1 (en) 2022-02-02 2025-04-24 Biotalys NV Methods for genome editing
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
JP2025507371A (ja) 2022-02-11 2025-03-18 ヘンケル・アクチェンゲゼルシャフト・ウント・コムパニー・コマンディットゲゼルシャフト・アウフ・アクチェン α－メチレン－γ－ブチロラクトンを合成する方法
US20250144042A1 (en) 2022-02-22 2025-05-08 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
CA3246434A1 (en) 2022-03-23 2023-09-28 Bodhi Bio Llc COMPOSITIONS AND METHODS FOR SPECIFIC ANTIGEN THERAPY
US20250223370A1 (en) 2022-03-30 2025-07-10 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
US20250333515A1 (en) 2022-04-11 2025-10-30 Vor Biopharma Inc. Binding agents and methods of use thereof
EP4508082A1 (en) 2022-04-13 2025-02-19 Vib Vzw An ltbr agonist in combination therapy against cancer
JP2025512483A (ja) 2022-04-13 2025-04-17 オーエスイー・イミュノセラピューティクス 抗体を選択的に排除するための分子の新規のクラス
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
EP4514390A1 (en) 2022-04-28 2025-03-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
US20250289904A1 (en) 2022-05-02 2025-09-18 Umc Utrecht Holding B.V. Single domain antibodies for the detection of plasmin-cleaved vwf
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
EP4524156A4 (en) 2022-05-07 2025-10-22 Beijing Tuo Jie Biopharmaceutical Co Ltd RELAXIN FUSION PROTEIN OR ANALOGUE AND ITS MEDICAL USE
JP2025517657A (ja) 2022-05-10 2025-06-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル シンシチン－１融合タンパク質及び標的細胞へのカーゴ送達のためのその使用
JP2025516629A (ja) 2022-05-11 2025-05-30 セルジーン コーポレーション Ｔ細胞療法に関連する方法および使用、ならびにその生成
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
TWI866210B (zh) 2022-05-17 2024-12-11 大陸商蘇州創勝醫藥集團有限公司 雙功能蛋白質及其製劑和用途
IL316708A (en) 2022-05-18 2024-12-01 Vib Vzw Cerbevirus S2 spike subunit binding
US20230372395A1 (en) 2022-05-19 2023-11-23 Massachusetts Institute Of Technology Car cells targeting an inserted ligand
WO2023224412A1 (ko) 2022-05-19 2023-11-23 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
US20240025987A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
CN119301276A (zh) 2022-05-30 2025-01-10 Ose免疫疗法 Il7r调节剂活性的生物标志物
JP2025518269A (ja) 2022-05-31 2025-06-12 明済生物製薬（北京）有限公司 抗ｃｄ４０抗体と抗ｐｄ－ｌ１×ｃｄ４０二重特異性抗体及びその使用
IL317463A (en) 2022-06-06 2025-02-01 Shandong Simcere Biopharmaceutical Co Ltd Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
AU2023290487A1 (en) 2022-06-14 2025-01-30 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
EP4299124A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 nanobodies for use as biomolecule transporter
EP4299125A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 biparatopic nanobodies and uses thereof
US20250304677A1 (en) 2022-07-04 2025-10-02 Vib Vzw Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
CA3259753A1 (en) 2022-07-08 2024-01-11 Novo Nordisk As HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF REPLACED FVIII(A)
AR129879A1 (es) 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
PE20250669A1 (es) 2022-07-15 2025-03-04 Boehringer Ingelheim Int Moleculas de union para el tratamiento del cancer
KR20250040019A (ko) 2022-07-18 2025-03-21 아블린쓰 Cx3cr1 결합 화합물, 이의 용도, 및 관련 방법
US20250188492A1 (en) 2022-07-22 2025-06-12 Janssen Biotech, Inc. Enhanced Transfer of Genetic Instructions to Effector Immune Cells
EP4562155A2 (en) 2022-07-25 2025-06-04 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
JP2025526384A (ja) 2022-07-27 2025-08-13 アブリンクス エン．ヴェー． 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
JP2025525884A (ja) 2022-08-01 2025-08-07 オーエスイー・イミュノセラピューティクス ヘテロ二量体Ｆｃ－ＣＬＥＣ－１融合分子及びその使用
CN119907811A (zh) 2022-08-02 2025-04-29 Ose免疫疗法公司 针对cd28的多功能分子
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
JP2025528459A (ja) 2022-08-31 2025-08-28 アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル（インセルム） より効率的なｃａｒ－ｔ細胞を生成する方法
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
CN120035450A (zh) 2022-09-06 2025-05-23 阿雷克森制药公司 造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱
WO2024228717A2 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
AU2023338626A1 (en) 2022-09-09 2025-03-20 Yale University Proteolysis targeting antibodies and methods of use thereof
IL319225A (en) 2022-09-15 2025-04-01 Novartis Ag Treatment of autoimmune disorders using antigen receptor chemotherapeutics
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
KR20250131767A (ko) 2022-09-28 2025-09-03 발린크 테라퓨틱스 리미티드 다가 단백질 및 스크리닝 방법
TW202430561A (zh) 2022-09-30 2024-08-01 法商賽諾菲公司 抗cd28抗體
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
CN120322456A (zh) 2022-10-28 2025-07-15 嘉和生物药业有限公司 新型抗ctla4抗体
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
CN117986361A (zh) 2022-11-02 2024-05-07 苏州康宁杰瑞生物科技有限公司 一种gipr结合蛋白及其应用
EP4615493A1 (en) 2022-11-08 2025-09-17 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
CN120584135A (zh) 2022-11-10 2025-09-02 英姆维亚公司 结合dr5和muc16的细胞毒性双特异性抗体及其用途
JP2025537809A (ja) 2022-11-15 2025-11-20 アイメック・ヴェーゼットウェー 液滴操作のための方法およびシステム
US12110344B2 (en) 2022-11-21 2024-10-08 Dianthus Therapeutics Opco, Inc. Antibodies that bind to cis and uses thereof
TW202421667A (zh) 2022-11-29 2024-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｌｄｎ１８．２／４－１ｂｂ結合蛋白及其醫藥用途
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
AU2023406483A1 (en) 2022-12-01 2025-05-29 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
WO2024126363A1 (en) 2022-12-12 2024-06-20 Institut National de la Santé et de la Recherche Médicale Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
AU2023394987A1 (en) 2022-12-15 2025-06-26 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
AU2023410327A1 (en) 2022-12-19 2025-06-05 Umc Utrecht Holding B.V. Btn2a1 binding peptide
CN120380024A (zh) 2022-12-21 2025-07-25 建新公司 抗pd-1×4-1bb结合蛋白
EP4638735A1 (en) 2022-12-22 2025-10-29 Biotalys NV Methods for genome editing
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
EP4640715A1 (en) 2022-12-23 2025-10-29 Chimagen Biosciences, Ltd Multi-specific polypeptide complex targeting gprc5d
WO2024145551A1 (en) 2022-12-29 2024-07-04 Biotalys NV Agrochemical compositions
EP4643878A2 (en) 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Pharmaceutical preparation comprising therapeutic antibody and use thereof
EP4642232A1 (en) 2022-12-30 2025-11-05 Biotalys NV Self-emulsifiable concentrate
EP4642916A2 (en) 2022-12-30 2025-11-05 Biotalys NV Secretion signals
WO2024141645A1 (en) 2022-12-30 2024-07-04 Biotalys N.V. Agglomerate
EP4647771A1 (en) 2022-12-30 2025-11-12 UIF (University Industry Foundation), Yonsei University Antibody or peptide binding specifically to rnase a, immunoassay device and method for detecting rnase a, and method for collecting rnase a
TW202434643A (zh) 2023-01-09 2024-09-01 大陸商北京拓界生物醫藥科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途
KR20250133750A (ko) 2023-01-09 2025-09-08 오디세이 테라퓨틱스, 인코포레이티드 항-tnfr2 항원-결합 단백질 및 그의 용도
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
TW202434629A (zh) 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
EP4655324A1 (en) 2023-01-27 2025-12-03 Vib Vzw Cd163-binding conjugates
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
KR20250143339A (ko) 2023-02-06 2025-10-01 메르크 파텐트 게엠베하 VHH-기반 NKp46 결합제
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
WO2024165710A1 (en) 2023-02-09 2024-08-15 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
KR20250133776A (ko) 2023-02-10 2025-09-08 아뮤닉스 파마슈티컬스, 인크. 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
AR132062A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cd3 y métodos de uso
AR132064A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos anti-cldn6 y métodos de uso
AR132063A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
AU2024234615A1 (en) 2023-03-14 2025-08-21 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
US20240344078A1 (en) 2023-03-14 2024-10-17 Aarhus Universitet Genetically altered nfr5 receptor kinases
AU2024240821A1 (en) 2023-03-23 2025-11-06 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
AU2024247861A1 (en) 2023-03-24 2025-11-06 Sanofi Asthma treatment by blocking il-13 and tslp
EP4435005A1 (en) 2023-03-24 2024-09-25 Sanofi Asthma treatment by blocking il-13 and tslp
WO2024200846A1 (en) 2023-03-30 2024-10-03 272BIO Limited Gnrh-binding polypeptides and uses thereof
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
WO2024224323A1 (en) 2023-04-24 2024-10-31 King Abdullah University Of Science Of Technology Compositions, systems and methods for multiplex detection of target biomarkers in a sample
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
TW202509060A (zh) 2023-05-08 2025-03-01 法商賽諾菲公司 免疫球蛋白單可變結構域的醣基化
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024238565A1 (en) 2023-05-15 2024-11-21 Vor Biopharma Inc. Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
AR132699A1 (es) 2023-05-17 2025-07-23 Odyssey Therapeutics Inc Anticuerpos de dominio único modificados
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024251783A1 (en) 2023-06-05 2024-12-12 Sanofi Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024251983A1 (en) 2023-06-09 2024-12-12 Merck Patent Gmbh Il-18 mimetics
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2024261338A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Immunoglobulin single variable domains targeting pd-l1
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
AR133108A1 (es) 2023-06-29 2025-08-27 Odyssey Therapeutics Inc Proteínas de unión a antígeno anti-trailr2 y sus usos
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032213A1 (en) 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification of hla-dra as a ligand of clec-1 and uses thereof
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025078418A1 (en) 2023-10-10 2025-04-17 Nano Tag Biotechnologies Gmbh Humanized single-domain antibodies binding to epitope tags
WO2025078401A1 (en) 2023-10-11 2025-04-17 BioNTech SE Agents and methods for targeted delivery of immune effector cells
TW202515903A (zh) 2023-10-12 2025-04-16 瑞士商百濟神州瑞士有限責任公司 手術前後基於抗ｐｄ－１之治療
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025132833A1 (en) 2023-12-20 2025-06-26 Institut National de la Santé et de la Recherche Médicale Anti trypsin-3 single domain antibody
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025133252A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Immunoglobulin single variable domains targeting ceacam5
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
EP4574981A1 (en) 2023-12-22 2025-06-25 Biotalys NV Anti-fungal vhh antibodies
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025160546A1 (en) 2024-01-26 2025-07-31 The Johns Hopkins University Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US20250269052A1 (en) 2024-02-27 2025-08-28 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025207946A1 (en) 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2025212726A2 (en) 2024-04-04 2025-10-09 Compass Therapeutics, Inc. Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238157A1 (en) 2024-05-15 2025-11-20 Katholieke Universiteit Leuven Multispecific binding agent suitable for use in cancer immune therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001787A1 (en) * 1990-07-25 1992-02-06 Cambridge Antibody Technology Limited Binding domains

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001787A1 (en) * 1990-07-25 1992-02-06 Cambridge Antibody Technology Limited Binding domains

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Blier et al., "A Limited Number of B Cell Lineages Generates The Heterogeneity Of A Secondary Immune Response", J. Immunology, vol. 139, No. 12, pp. 3996-4006 (Dec. 15, 1987).
Blier et al., A Limited Number of B Cell Lineages Generates The Heterogeneity Of A Secondary Immune Response , J. Immunology, vol. 139, No. 12, pp. 3996 4006 (Dec. 15, 1987). *
Hamers Casterman et al., Nature , 363:446 48 (1993). *
Hamers-Casterman et al., "Nature", 363:446-48 (1993).
Roitt et al., "Immunology", Gower Medical Publishing, London, pp. 1.5 and 5.7 (1985).
Roitt et al., Immunology , Gower Medical Publishing, London, pp. 1.5 and 5.7 (1985). *
Ward et al., "Nature", 341:544-546 (1989).
Ward et al., Nature , 341:544 546 (1989). *
Webster s II New Riverside University Dictionary, The Riverside Publishing Co./Houghton Mifflin Co., Boston, MA, 1995. *
Webster's II New Riverside University Dictionary, The Riverside Publishing Co./Houghton Mifflin Co., Boston, MA, 1995.

Cited By (335)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134107A1 (en) * 1992-08-21 2006-06-22 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US20040253638A1 (en) * 1992-08-21 2004-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US20060121026A1 (en) * 1992-08-21 2006-06-08 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US7722871B2 (en) 1992-08-21 2010-05-25 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US20070077240A1 (en) * 1992-08-21 2007-04-05 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US20070238133A1 (en) * 1992-08-21 2007-10-11 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US7786047B2 (en) 1992-08-21 2010-08-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US7790367B2 (en) 1992-08-21 2010-09-07 Vrije Universiteit Brussel Method for screening a library of VHH polypeptides
US20070025985A1 (en) * 1992-08-21 2007-02-01 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
US8071104B2 (en) 1999-07-01 2011-12-06 Yale University Neovascular-targeted immunoconjugates
US8388974B2 (en) 1999-07-01 2013-03-05 Yale University Neovascular-targeted immunoconjugates
US7858092B2 (en) 1999-07-01 2010-12-28 Yale University Neovascular-targeted immunoconjugates
US20110117114A1 (en) * 1999-07-01 2011-05-19 Yale University Neovascular-Targeted Immunoconjugates
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US7887809B1 (en) 1999-07-01 2011-02-15 Yale University Neovascular-targeted immunoconjugates
US20050214298A1 (en) * 1999-07-01 2005-09-29 Yale University Neovascular-targeted immunoconjugates
EP2198882A2 (en) 2001-01-12 2010-06-23 Novartis Vaccines and Diagnostics, Inc. Nucleic acid mucosal immunization
US8188237B2 (en) 2001-01-17 2012-05-29 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US20110091461A1 (en) * 2001-01-17 2011-04-21 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20110105729A1 (en) * 2001-01-17 2011-05-05 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20100034820A1 (en) * 2001-01-17 2010-02-11 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US8147835B2 (en) 2001-01-17 2012-04-03 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20050202028A1 (en) * 2001-01-17 2005-09-15 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050136049A1 (en) * 2001-01-17 2005-06-23 Ledbetter Jeffrey A. Binding constructs and methods for use thereof
US20110223164A1 (en) * 2001-01-17 2011-09-15 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US9005612B2 (en) 2001-01-17 2015-04-14 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8106161B2 (en) 2001-01-17 2012-01-31 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8197810B2 (en) 2001-01-17 2012-06-12 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8853366B2 (en) 2001-01-17 2014-10-07 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US6861056B2 (en) 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20040086508A1 (en) * 2001-06-05 2004-05-06 Advanced Biotherapy, Inc. Treatment of organ transplant rejection
US7115263B2 (en) 2001-06-05 2006-10-03 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20070065442A1 (en) * 2001-06-05 2007-03-22 Boris Skurkovich Compositions and methods for treating hyperimmune response in the eye
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20050152902A1 (en) * 2001-06-05 2005-07-14 Advanced Biotherapy, Inc. Treatment of diabetic retinopathy
US20050175613A1 (en) * 2001-06-05 2005-08-11 Boris Skurkovich Compositions and methods for treating hyperimmune response in the eye
US20030215448A1 (en) * 2001-06-05 2003-11-20 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20070031430A1 (en) * 2002-01-03 2007-02-08 Vlaams Interuniversitair Instituut Immunoconjugates
US20050048060A1 (en) * 2002-01-03 2005-03-03 Hilde Revets Immunoconjugates
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US20060063921A1 (en) * 2002-06-28 2006-03-23 Domantis Limited Ligand
US20060193860A1 (en) * 2002-09-18 2006-08-31 Boris Skurkovich Treatment of schizophrenia
US20040052792A1 (en) * 2002-09-18 2004-03-18 Advanced Biotherapy, Inc. Treatment of schizophrenia
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
US20100279932A1 (en) * 2003-07-26 2010-11-04 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005044998A2 (en) 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody
US20070180542A1 (en) * 2004-04-12 2007-08-02 The Trustees Of The University Of Pennsylvania Culture conditions and growth factors affecting fate determination, self-renewal and expansion of rat spermatogonial stem cells
US20070192881A1 (en) * 2004-04-12 2007-08-16 The Trustees Of The University Of Pennsylvania Culture conditions and growth factors affecting fate determination, self-renewal and expansion of rat spermatogonial stem cells
US20060188505A1 (en) * 2004-06-15 2006-08-24 Advanced Biotherapy, Inc. Treatment of autism
US20060182747A1 (en) * 2004-06-15 2006-08-17 Advanced Biotherapy, Inc. Treatment of autism
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
US20060177445A1 (en) * 2004-08-16 2006-08-10 Boris Skurkovich Treatment of inflammatory skin diseases
US7927596B2 (en) 2004-09-17 2011-04-19 Domantis Limited Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptides
US20060062784A1 (en) * 2004-09-17 2006-03-23 Domantis Limited Compositions monovalent for CD40L binding and methods of use
US7829096B2 (en) 2004-09-17 2010-11-09 Domantis Ltd. CD40L-specific monovalent polypeptides
US20090297524A1 (en) * 2004-09-17 2009-12-03 Steven Grant Compositions monovalent for CD40L binding and methods of use
US20100092482A1 (en) * 2004-09-17 2010-04-15 Domantis Limited Compositions monovalent for CD40L binding and methods of use
EP2371862A2 (en) 2004-09-17 2011-10-05 Domantis Limited Compositions monovalent for CD40L binding and methods of use
US20100092483A1 (en) * 2004-09-17 2010-04-15 Domantis Limited Compositions monovalent for CD40L binding and methods of use
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US8524236B2 (en) 2004-09-17 2013-09-03 Domantis Limited Methods of antagonizing the binding of CD40 to CD40L with CD40L-specific monovalent polypeptides in autoimmune individuals
US20110172400A1 (en) * 2004-09-17 2011-07-14 Domantis Limited Compositions monovalent for cd40l binding and methods of use
US7462454B2 (en) 2004-10-12 2008-12-09 Advanced Biotherapy, Inc. Treatment of herpes
US20060194221A1 (en) * 2004-10-12 2006-08-31 Boris Skurkovich Treatment of herpes
US11359185B2 (en) 2005-04-28 2022-06-14 Ventana Medical Systems, Inc. Antibody conjugates
US20090176253A1 (en) * 2005-04-28 2009-07-09 Christopher Bieniarz Antibody conjugates
US20060246523A1 (en) * 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
US9315789B2 (en) 2005-04-28 2016-04-19 Ventana Medical Systems, Inc. Antibody conjugates
US8658389B2 (en) 2005-04-28 2014-02-25 Ventana Medical Systems, Inc. Antibody conjugates
US20060246524A1 (en) * 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
EP3144675A1 (en) 2005-04-28 2017-03-22 Ventana Medical Systems, Inc. Enzymes conjugated to antibodies via a peg heterobifuctional linker
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
US20070059306A1 (en) * 2005-07-25 2007-03-15 Trubion Pharmaceuticals, Inc. B-cell reduction using CD37-specific and CD20-specific binding molecules
US10143748B2 (en) 2005-07-25 2018-12-04 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US20090214539A1 (en) * 2005-07-25 2009-08-27 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
US20070083564A1 (en) * 2005-10-07 2007-04-12 Ramacher Mark C Automatic performance statistical comparison between two periods
US20070117153A1 (en) * 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
US20100136652A1 (en) * 2005-11-23 2010-06-03 Christopher Bieniarz Molecular Conjugate
EP2963011A1 (en) 2005-11-23 2016-01-06 Ventana Medical Systems, Inc. Molecular conjugate
US8686122B2 (en) 2005-11-23 2014-04-01 Ventana Medical Systems, Inc. Molecular conjugate
US9310373B2 (en) 2005-11-23 2016-04-12 Ventana Medical Systems, Inc. Molecular conjugate
US20090148446A1 (en) * 2006-03-14 2009-06-11 Boris Skurkovich Method and Composition for Treatment of Renal Failure with Antibodies and Their Equivalents as Partial or Complete Replacement for Dialysis
US20070218063A1 (en) * 2006-03-14 2007-09-20 Boris Skurkovich Method and composition for treatment of renal disease with antibodies and their equivalents
US8784822B2 (en) 2006-03-14 2014-07-22 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US20100226920A1 (en) * 2006-03-27 2010-09-09 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
US20080070268A1 (en) * 2006-04-21 2008-03-20 Wyeth Differential expression profiling analysis of cell culture phenotypes and the uses thereof
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US20110033483A1 (en) * 2006-06-12 2011-02-10 Trubion Pharmaceuticals Inc. Single-chain multivalent binding proteins with effector function
EP2495307A1 (en) 2006-07-13 2012-09-05 Wyeth LLC Production of glycoproteins
EP3255141A1 (en) 2006-07-13 2017-12-13 Wyeth LLC Production of antibodies with improved glycosylation pattern
EP3276349A1 (en) 2006-11-01 2018-01-31 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US8618265B2 (en) 2006-11-01 2013-12-31 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
EP3564674A1 (en) 2006-11-01 2019-11-06 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US8846320B2 (en) 2006-11-01 2014-09-30 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
WO2008063378A2 (en) 2006-11-01 2008-05-29 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US9719986B2 (en) 2006-11-01 2017-08-01 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use
EP2444806A2 (en) 2006-11-01 2012-04-25 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
EP2444807A2 (en) 2006-11-01 2012-04-25 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
EP2442107A2 (en) 2006-11-01 2012-04-18 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20100184087A1 (en) * 2006-11-01 2010-07-22 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
EP3029461A1 (en) 2006-11-01 2016-06-08 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US7695929B2 (en) 2006-11-01 2010-04-13 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20100297725A1 (en) * 2006-11-01 2010-11-25 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US12084519B2 (en) 2007-02-20 2024-09-10 Trustees Of Tufts College Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US9834616B2 (en) 2007-02-20 2017-12-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US11091563B2 (en) 2007-02-20 2021-08-17 Trustees Of Tufts College Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US9012180B2 (en) 2007-03-02 2015-04-21 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
WO2008109410A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
US20090068705A1 (en) * 2007-03-02 2009-03-12 Wyeth Use of Copper Glutamate in Cell Culture for Production of Polypeptides
EP2924113A1 (en) 2007-03-02 2015-09-30 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
US8486620B2 (en) 2007-05-23 2013-07-16 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US8445191B2 (en) 2007-05-23 2013-05-21 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US9103822B2 (en) 2007-05-23 2015-08-11 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
EP3561513A1 (en) 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US9575067B2 (en) 2007-05-23 2017-02-21 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US20080305497A1 (en) * 2007-05-23 2008-12-11 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US9017954B2 (en) 2007-05-23 2015-04-28 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
EP2602323A1 (en) 2007-06-01 2013-06-12 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
WO2008151081A1 (en) 2007-06-01 2008-12-11 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
EP3382022A1 (en) 2007-06-01 2018-10-03 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
EP2336329A1 (en) 2007-06-01 2011-06-22 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies
US20090017460A1 (en) * 2007-06-15 2009-01-15 Wyeth Differential expression profiling analysis of cell culture phenotypes and uses thereof
WO2009012181A2 (en) 2007-07-13 2009-01-22 Ventana Medical Systems, Inc. Method of identifying diagnostic reagents
EP2902494A1 (en) 2007-11-09 2015-08-05 The Salk Institute for Biological Studies Use of tam receptor inhibitors as antimicrobials
EP2902495A1 (en) 2007-11-09 2015-08-05 The Salk Institute for Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
US20090186358A1 (en) * 2007-12-21 2009-07-23 Wyeth Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
US8333966B2 (en) 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
US9101609B2 (en) 2008-04-11 2015-08-11 Emergent Product Development Seattle, Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20110171208A1 (en) * 2008-04-11 2011-07-14 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2995925A1 (en) 2008-06-05 2016-03-16 Ventana Medical Systems, Inc. Composition for histochemical processing
US8703490B2 (en) 2008-06-05 2014-04-22 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
US10718693B2 (en) 2008-06-05 2020-07-21 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
EP2700651A1 (en) 2008-07-18 2014-02-26 Bristol-Myers Squibb Company Compositions monovalent for CD28 binding and methods of use
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100189919A1 (en) * 2009-01-27 2010-07-29 Xerox Corporation Imaging System And Process Using Monoclonal Antibodies
EP2230515A1 (en) 2009-03-16 2010-09-22 Polymer Laboratories Limited Passivation of surfaces after ligand coupling
US9709563B2 (en) 2009-03-16 2017-07-18 Agilent Technologies, Inc. Passivation of surfaces after ligand coupling
US20100233734A1 (en) * 2009-03-16 2010-09-16 Roderick Nicholas Hobbs Passivation of surfaces after ligand coupling
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
US9255148B2 (en) 2009-09-03 2016-02-09 Cancer Research Technology Limited CLEC14A inhibitors
US20110145937A1 (en) * 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice That Make Heavy Chain Antibodies
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US11234419B2 (en) 2009-12-10 2022-02-01 Regeneran Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US9888675B2 (en) 2009-12-10 2018-02-13 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
WO2011072266A2 (en) 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
WO2011106583A1 (en) 2010-02-26 2011-09-01 Ventana Medical Systems, Inc. Polytag probes
WO2011128701A2 (en) 2010-04-16 2011-10-20 Imperial Innovations Limited Cancer methods
WO2011133625A1 (en) 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
WO2011139907A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
WO2011139854A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
WO2011140267A2 (en) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
WO2012003476A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US10954310B2 (en) 2010-08-02 2021-03-23 Regeneran Pharmaceuticals, Inc. Mice that make VL binding proteins
US9127028B2 (en) 2010-08-16 2015-09-08 Ventana Medical Systems, Inc. Substrates for chromogenic detection and methods of use in detection assays and kits
WO2012024185A1 (en) 2010-08-16 2012-02-23 Ventana Medical Systems, Inc. Substrates for chromogenic detection and methods of use in detection assays and kits
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
WO2012089814A1 (en) 2010-12-30 2012-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
US8871442B2 (en) 2010-12-30 2014-10-28 Ventana Medical Systems, Inc. Enhanced deposition of chromogens
WO2012092322A1 (en) 2010-12-30 2012-07-05 Ventana Medical Systems, Inc. Enhanced deposition of chromogens utilizing pyrimidine analogs
US9435795B2 (en) 2010-12-30 2016-09-06 Ventana Medical Systems, Inc. Enhanced deposition of chromogens utilizing pyrimidine analogs
US9562259B2 (en) 2011-03-14 2017-02-07 Ventana Medical Systems, Inc. Method of analyzing chromosomal inversions
WO2012123387A1 (en) 2011-03-14 2012-09-20 F. Hoffmann-La Roche Ag A method of analyzing chromosomal translocations and a system therefore
WO2012166906A1 (en) 2011-05-31 2012-12-06 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
WO2013033073A1 (en) 2011-08-31 2013-03-07 Ventana Medical Systems, Inc. Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
WO2013034933A1 (en) 2011-09-08 2013-03-14 Imperial Innovations Limited Anti ddr1 antibodies, their uses and methods identifying them
WO2013041901A1 (en) 2011-09-20 2013-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing single domain antibody microarrays
WO2013079606A1 (en) 2011-12-01 2013-06-06 Ventana Medical Systems, Inc. Automated dual stain of mirna and protein targets
WO2013079973A1 (en) 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10738109B2 (en) 2012-01-09 2020-08-11 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
WO2013108126A2 (en) 2012-01-16 2013-07-25 University Of Oslo Methyltransferases and uses thereof
WO2013148498A1 (en) 2012-03-27 2013-10-03 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US10557851B2 (en) 2012-03-27 2020-02-11 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US10041950B2 (en) 2012-03-27 2018-08-07 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US11906523B2 (en) 2012-03-27 2024-02-20 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US9982247B2 (en) 2012-07-19 2018-05-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for purifying transgenic factor VII/VIIA
EP3184121A2 (en) 2012-07-25 2017-06-28 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
EP3653049A1 (en) 2012-12-14 2020-05-20 Open Monoclonal Technology, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
EP4269602A2 (en) 2012-12-14 2023-11-01 OmniAB, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
US12126880B2 (en) 2013-03-12 2024-10-22 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
WO2014143155A1 (en) 2013-03-12 2014-09-18 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
EP3764083A1 (en) 2013-03-12 2021-01-13 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
EP3764084A1 (en) 2013-03-12 2021-01-13 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
US10778913B2 (en) 2013-03-12 2020-09-15 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
US11070750B2 (en) 2013-03-12 2021-07-20 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
US10202441B2 (en) 2013-12-26 2019-02-12 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
US10766950B2 (en) 2013-12-26 2020-09-08 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US10881085B2 (en) 2014-03-21 2021-01-05 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US10787522B2 (en) 2014-03-21 2020-09-29 Regeneron Pharmaceuticals, Inc. VL antigen binding proteins exhibiting distinct binding characteristics
WO2016054522A1 (en) 2014-10-03 2016-04-07 Ntercept, Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
US12065486B2 (en) 2014-12-10 2024-08-20 Trustees Of Tufts College VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
US10808031B2 (en) 2015-01-21 2020-10-20 Cancer Research Technology Limited Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
WO2016116760A2 (en) 2015-01-21 2016-07-28 Cancer Research Technology Limited Inhibitors
US11919959B2 (en) 2015-01-21 2024-03-05 Cancer Research Technology Limited Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016166110A1 (en) 2015-04-13 2016-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
US9778265B2 (en) 2015-04-16 2017-10-03 The United States Of America, As Represented By The Secretary Of The Navy Charged peptide appendage to facilitate oriented protein covalent immobilization
US12084518B2 (en) 2015-05-21 2024-09-10 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US10954311B2 (en) 2015-05-21 2021-03-23 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
US9920115B2 (en) 2016-05-20 2018-03-20 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US10544221B2 (en) 2016-05-20 2020-01-28 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10066016B2 (en) 2016-05-20 2018-09-04 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11453716B2 (en) 2016-05-20 2022-09-27 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
WO2018078083A1 (en) 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
US10849973B2 (en) 2016-11-23 2020-12-01 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018136823A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US12016313B2 (en) 2017-01-19 2024-06-25 Omniab Operations, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
WO2018141753A1 (en) 2017-01-31 2018-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating squamous cell carcinomas
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
US11607453B2 (en) 2017-05-12 2023-03-21 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
US12371504B2 (en) 2017-10-13 2025-07-29 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US10927180B2 (en) 2017-10-13 2021-02-23 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
US11136403B2 (en) 2017-10-13 2021-10-05 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US11976125B2 (en) 2017-10-13 2024-05-07 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019197683A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
US12415860B2 (en) 2018-05-14 2025-09-16 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
WO2020016160A1 (en) 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
WO2020049130A1 (en) 2018-09-05 2020-03-12 Valerie Nicholas Carl Kristoffer Methods
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US11807692B2 (en) 2018-09-25 2023-11-07 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020089273A1 (en) 2018-10-31 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating t-helper type 2 mediated disease
WO2020148349A1 (en) 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2020208082A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
WO2020229546A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
WO2020229648A1 (en) 2019-05-16 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat type 2 inflammation or mast-cell dependent disease
WO2020245160A1 (en) 2019-06-03 2020-12-10 Fenomark Diagnostics Ab Medical uses, methods and uses
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
WO2021046159A1 (en) 2019-09-04 2021-03-11 Genentech, Inc. Cd8 binding agents and uses thereof
WO2021044012A1 (en) 2019-09-05 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
WO2021058744A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
WO2021105391A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination comprising nupr1 inhibitors to treat cancer
WO2021105384A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
US11180563B2 (en) 2020-02-21 2021-11-23 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
WO2021233962A1 (en) 2020-05-19 2021-11-25 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
EP4424711A2 (en) 2020-05-19 2024-09-04 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
WO2021255204A1 (en) 2020-06-18 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
WO2022084399A1 (en) 2020-10-21 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) C-terminal sparc fragments for treating cancer
WO2022162192A2 (en) 2021-01-29 2022-08-04 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2022171777A1 (en) 2021-02-12 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for prognosis and treating a patient suffering from cancer
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
WO2022219076A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
WO2022253910A1 (en) 2021-06-02 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) A new method to treat an inflammatory skin disease
WO2023012343A1 (en) 2021-08-06 2023-02-09 Institut Du Cancer De Montpellier Methods for the treatment of cancer
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023073099A1 (en) 2021-10-28 2023-05-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2023078906A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating acute myeloid leukemia
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
US12486335B2 (en) 2021-12-14 2025-12-02 Regeneron Pharmaceuticals, Inc. Mice that make VL binding proteins
WO2023144392A1 (en) 2022-01-28 2023-08-03 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
WO2024028476A1 (en) 2022-08-05 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en) 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer
WO2024049951A1 (en) 2022-08-31 2024-03-07 Alexion Pharmaceuticals, Inc. Dosage and administration of fusion polypeptides for treatment of sickle cell disease
WO2024123963A2 (en) 2022-12-07 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
WO2024184476A1 (en) 2023-03-07 2024-09-12 Institut Curie Ung/udg inhibition in brca-associated cancer
WO2024184479A1 (en) 2023-03-08 2024-09-12 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of food allergy
WO2024194401A1 (en) 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194692A1 (en) 2023-03-21 2024-09-26 Institut Curie Tgf-beta inhibitor for use in the treatment of dedifferentiated liposarcoma
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024213782A1 (en) 2023-04-13 2024-10-17 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024256527A1 (en) 2023-06-13 2024-12-19 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
WO2025024645A1 (en) 2023-07-25 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rapid method for producing antibodies
WO2025032112A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of type 2-mediated diseases
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078851A1 (en) 2023-10-11 2025-04-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of treating cognitive deficit
WO2025162980A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of breast cancer using a jnk-1 inhibitor
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
WO2025191018A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025231143A1 (en) 2024-04-30 2025-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against ev-d68

Also Published As

Publication number Publication date
EP2192131A1 (en) 2010-06-02
US5840526A (en) 1998-11-24
CA2142331C (en) 2010-02-02
DE69330523T4 (de) 2012-08-23
PT1087013E (pt) 2009-04-15
ATE452207T1 (de) 2010-01-15
EP1621554B1 (en) 2009-04-08
FI117975B (fi) 2007-05-15
FI20041584L (fi) 2004-12-08
WO1994004678A1 (en) 1994-03-03
ATE452975T1 (de) 2010-01-15
DE69334305D1 (de) 2010-01-28
ATE427968T1 (de) 2009-04-15
AU4949793A (en) 1994-03-15
JP2002053600A (ja) 2002-02-19
ES2162823T5 (es) 2010-08-09
EP1589107A1 (en) 2005-10-26
DE69334275D1 (de) 2009-05-20
EP1621554B2 (en) 2012-08-29
US5874541A (en) 1999-02-23
EP0656946B2 (en) 2010-03-31
ES2322324T3 (es) 2009-06-19
EP1498427A1 (en) 2005-01-19
DK1087013T3 (da) 2009-05-11
JPH08500487A (ja) 1996-01-23
DK1498427T3 (da) 2010-04-26
DK0656946T3 (da) 2001-11-05
DE69334308D1 (de) 2010-02-04
ES2162823T3 (es) 2002-01-16
DK1621554T3 (da) 2009-08-10
EP1621554A1 (en) 2006-02-01
EP1087013A2 (en) 2001-03-28
DE69330523T3 (de) 2010-10-28
DE69330523T2 (de) 2002-03-28
FI20070170L (fi) 2007-02-28
US5759808A (en) 1998-06-02
PT656946E (pt) 2001-12-28
EP1087013A3 (en) 2001-11-28
AU701578B2 (en) 1999-02-04
JP4414900B2 (ja) 2010-02-10
DK1621554T4 (da) 2012-12-17
CA2142331A1 (en) 1994-03-03
DE69334258D1 (de) 2009-02-26
ES2338791T3 (es) 2010-05-12
EP1087013B1 (en) 2009-01-07
FI950782A0 (fi) 1995-02-20
JP3444885B2 (ja) 2003-09-08
FI120404B (fi) 2009-10-15
ATE203767T1 (de) 2001-08-15
FI950782A7 (fi) 1995-04-20
EP1498427B1 (en) 2009-12-16
FI115462B (fi) 2005-05-13
DE69330523D1 (de) 2001-09-06
ES2338321T3 (es) 2010-05-06
ES2325541T3 (es) 2009-09-08
JP2009280608A (ja) 2009-12-03
DK0656946T4 (da) 2010-07-26
US5800988A (en) 1998-09-01
EP0656946A1 (en) 1995-06-14
PT1621554E (pt) 2009-07-13
GR3037024T3 (en) 2002-01-31
EP0656946B1 (en) 2001-08-01
PT1498427E (pt) 2010-03-22
DK1589107T3 (da) 2010-04-26
EP1589107B1 (en) 2009-12-23
JP2005170953A (ja) 2005-06-30
PT1589107E (pt) 2010-03-29
ATE420178T1 (de) 2009-01-15
JP3660270B2 (ja) 2005-06-15

Similar Documents

Publication Publication Date Title
US6015695A (en) Immunoglobulins devoid of light chains
US6005079A (en) Immunoglobulins devoid of light chains
US6765087B1 (en) Immunoglobulins devoid of light chains
EP0584421A1 (en) Immunoglobulins devoid of light chains
AU738133B2 (en) Immunoglobulins devoid of light chains
HK1074450A (en) Immunoglobulins devoid of light chains

Legal Events

Date Code Title Description
AS Assignment

Owner name: VRIJE UNIVERSITEIT BRUSSEL, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAMERS, RAYMOND;CASTERMAN, CECILE;REEL/FRAME:008375/0164

Effective date: 19961008

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12